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1. INTRODUCTION 
1.1. HERBAL MEDICINE 
Herbal medicine is defined as the therapeutically used plants to treat disease and to 
enhance general health and well being.   
Herb:  
Herb is a plant or plant part used for its scent, flavor or therapeutic properties. 
Herbal medicines are majorly given in the form of dietary supplement.   
Plants have been the basis for medical treatments throughout the  human history. 
Egyptian medicine by Papyri is considered to be a tomb illustration of medicinal plants1.  
Most important and lengthiest one is the Ebers papyrus dating from about 1550 
BC, and covering more than 700 drugs, mainly of plant origin2-3  
The Herbal medicine is still the mainstay of about 75 to 80% of the world’s total 
population, mainly in the developing countries. It is in greater demand for primary health 
care4. The use of Herbal remedies throughout the world exceeds by two to three times than 
conventional drugs5. Natural products are considered to be more effective than 
manufactured drugs6. 
Many conventional drugs originated from plant source: a century ago, which include  
¾ Aspirin (Willow bark)  
¾ Digoxin (Foxglove)  
¾ Quinine (From Chinchona bark)  
¾ Morphine (Opium poppy)7. 
 Even as we enter into the new century with its existing prospect of gene therapy, 
herbal medicines remains as one of the common forms of therapy available to the world 
population. The acceptance and recognition of the herbal medicine has been in part due to 
the acknowledgement of the value of traditional medicine in Indigenous Pharmacopoeias. 
Traditional Preparations comprised of Medicinal Plants, minerals and organic matters, 
etc4. 
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WHY HERBAL MEDICINE:  
It is often noted that “Sense of control, a mental comfort from taking action” which helps 
to explain why many people having chronic or incurable disease are taking herbs eg. 
Diabetes, Cancer, Arthritis or AIDS. In such situations, they often believe that 
conventional medicine has failed them. When patients use home remedies for acute, often 
self-limiting conditions, such as cold, sore throat, or bee sting, it is often because 
professional care is not immediately available, too inconvenient, costly or time-
consuming. The rural population is heavily dependent on traditional medical systems. 
SAFETY ISSUES IN HERBAL MEDICINES. 
Plant materials are used through developed and developing countries as home remedies, 
over-the-counter drug products and raw materials for the pharmaceutical industry, and 
represent a substantial proportion of the global drug market. It is therefore essential to 
establish internationally recognized guidelines for assessing their quality. The World 
Health Assembly – in resolutions WHA31.33 (1978), WHA40.30 (1987) and 
WHA42.43(1989) has emphasized the need to ensure the quality of  medicinal plant 
product by using modern control techniques and applying suitable standards (WHO, 
1998)8.  
Thus Latin Names, organoleptic, microscopic and technological analysis are important for 
the proper identification of the plants9.  
THE ROLE OF HERBAL MEDICINES IN TRADITIONAL HEALING: 
There are many traditional healing methods which are followed throughout the world 
some of them are 
Traditional Chinese medicine   
It has been used by Chinese people from ancient times. Although animal and mineral 
materials have been used, the primary source of remedies is botanical. Of the more than 12 
000 items used by traditional healers, about 500 are in common use (Li, 2000). Botanical 
products are used only after some kind of processing, which may include, for example, 
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stir-frying or soaking in vinegar or wine. In clinical practice, traditional diagnosis may be 
followed by the prescription of a complex and often individualized remedy. About 5000 
traditional remedies are available in China; they account for approximately one fifth of the 
entire Chinese pharmaceutical market10. 
Japanese traditional medicine 
Many herbal remedies found their way from China into the Japanese systems of 
traditional healing. Herbs native to Japan were classified in the first Pharmacopoeia of 
Japanese traditional medicine in the ninth century11. 
Indian traditional medicine 
Ayurveda is a medical system primarily practiced in India that has been known for nearly 
5000 years. It includes diet and herbal remedies, while emphasizing the body, mind and 
spirit in disease prevention and treatment12. 
India has a very long, safe and continuous usage of many herbal drugs in the officially 
recognized alternative systems of health. Ayurveda, Yoga, Unani, Siddha, Homeopathy 
and Naturopathy 13. 
Millions of Indians use herbal drugs regularly, as spices, home remedies, health foods as 
well as the OTC drugs as self-medication or also as drugs prescribed in the non-allopathic 
system14. 
IMPORTANCE OF HERBAL MEDICINE 
Medicinal plants are used at the house hold level to improve the health of the family 
members.  
These herbs are used in the various forms.  
 Food for growth 
 Food and herb as medicine15: 
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REASONS FOR THE USE OF NATURAL PRODUCTS16: 
 They provide a number of extremely useful drugs that are difficult, if not 
impossible, to produce commercially by synthetic means. They include alkaloid of 
Poppy, Ergot and Solanaceous.  
 Natural sources also supply basic compounds that may be modified slightly to 
render them more effective or less toxic. The numerous variations of the morphine 
molecule serve as example here.  
 Utility of natural products as prototypes or models for synthetic drug processing 
physiological activities similar to the original drug. Procaine and similar local 
anesthetics are commonly cited as representatives of this category. 
 Other important application is that the natural products contain compounds that 
demonstrate little or no activity themselves but which can be modified by chemical 
or biological methods to produce potent drugs not easily obtained by other 
methods.  
APPLICATION OF HERBAL MEDICINE17:  
 Herbal medicines have long history of use and better patient tolerance as well as 
acceptance 
 Medicinal plants have a renewable source, which is our only hope for sustainable 
supplies of cheaper medicines for the world growing population. 
 Availability of medicinal plants is not a problem especially in developing countries 
like India having rich agro-climatic, cultural and ethnic biodiversity  
 The cultivation and processing of medicinal herbs and herbal products is 
environmental friendly 
 Cost-effectiveness-prescription drugs cost much more money than herbal 
medicines 
 Lower side effects herbal medicines are generally a far heal their solution than 
prescription drugs due to potential harmful side effects caused by unpredicted body 
chemistry interactions. 
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PRESENT TRENDS IN HERBAL MEDICINE18:  
In many industries plants and plant- derived products are used for the treatment of various 
diseases. Hairy root culture is the powerful choice for producing active compound from 
medicinal plants.  
It provides faster growth and biochemical stability.  
Large amount of plant-derived pharmaceuticals can be obtained in a cheap and easy way.  
Usual forms of medicinal remedies: 
 Infusions 
 Decoctions 
 Tinctures 
 Syrups 
 Infused oils 
 Essential oils 
 Ointments 
 Creams  
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1.2. DISEASE PROFILE 
Brain is one of the most complex and magnificent organs in human body.  It hears, sees, 
feels, tastes, commands the limbs, talks, reads, writes, makes decisions and accomplishes 
numerous other functions.  Most importantly for our interests, it is an organ of memory.  
Our ears may hear the concert; our eyes may see the famous painting; our fingers may feel 
the silk nightgown; our nose may smell, our mouth may taste the delicious chocolate, but 
only our brain remembers what the experience was like, where it happened and the 
numerous other details involved. So, although the sensory abilities described above are not 
typically affected by Alzheimer’s disease, the memory of these experiences and perhaps 
the appreciation of them can be markedly affected. It controls our muscle movements, the 
secretions of our glands, and even our breathing and internal temperature. Every creative 
thought, feeling, and plan is developed by our brain. The brain’s neurons record the 
memory of every event in our lives.  
Human brain is one of the main organs of human Central Nervous System. It is present in 
the head and protected by skull. The general structure of all brains is similar as that of 
other mammals. Human brain is almost three times larger than that of a Chipamzee19.  
Adult human brain weighs on average about 1.3–1.5 kg (2.9–3.3 lb), or about 2% of total 
body weight20-21 with a volume of around 1130 cm3 in women and 1260 cm3 in men, 
although there is substantial individual variation.22 Neurological differences between the 
sexes have not been shown to correlate in any simple way with IQ or other measures of 
cognitive performance.23 
STRUCTURE OF BRAIN:  
Human brain is composed of several numbers of neurons, Glial cells and blood vessels. 
Brain is divided into three main parts, the cerebrum, the Cerebellum and the brain stem.  
The brain is divided into regions that control specific functions.  
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Fig 1:  Structure of brain 
THE CEREBRUM:  
It is further divided into four lobes 
Frontal lobe:  Behavior, Abstract thought processes, Problem solving, Attention, Creative 
thoughts, some emotion, Intellect, Reflection, Judgment, etc. 
Occipital lobe: Vision and reading 
Parietal lobe: Sense of touch (tactile sensation), Appreciation of form through touch 
(Stereognosis), Response to internal stimuli (Proprioception), Sensory combination and 
comprehension, some language and reading functions and some visual functions 
Temporal lobe: Auditory memories, some hearing, Visual memories, some vision 
pathways, other memory, Music, Fear, Some language, Some speech, Some behavior and 
emotions, Sense of identity. 
Right hemisphere: Controls left side of the body and analyze non verbal information.  
Left hemisphere:  The left hemisphere controls the right side of the body, Produce and 
understands language. 
Corpus collasum: Communication between the left and right side of the brain22 
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Fig 2:  Functional are of cerebral cortex. 
THE CEREBELLUM: 
 It is responsible for the balance, posture, cardiac, respiratory and vasomotor 
centers.  
THE BRAIN STEM: 
They are responsible for the Motor and sensory pathway of the body and face. It also 
controls the vital centers like respiratory, cardiac and vasomotor. 
Hypothalamus: It is responsible for the moods and motivation, sexual maturation, 
Temperature regulation and Hormonal body processes. 
Optic chiasm: Controls vision and the optic nerves 
Pituitary Gland: Hormonal body processes, Physical maturation, Growth, sexual 
maturation, sexual functioning.  
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Spinal cord: Conduit and source of sensation and movement.  
Pineal body: Ventricles and cerebral Aqueduct: Contain cerebrospinal fluid that bathes 
the brain and the spinal cord. 
Cerebral cortex plays a key role in memory, attention, perceptual awareness, thought, 
language and consciousness.  Hippocampus is located in cerebral cortex and associated the 
limbic system. Hippocampus has a special type of cells called place cells and its collection 
is called as cognitive maps24 
Spatial aspects of memory controlled by right side of hippocampus and context 
information controlled by left side of hippocampus25.  
Deep inside medial temporal lobe is the region of the brain known as the limbic system, 
which includes hippocampus, amygdala, cingulate gyrus, thalamus, hypothalamus, 
epithalamus, mammillary body and other organs, many of which are of particular 
relevance to the processing of memory.  Amygdala also performs a primary role in the 
processing and memory of emotional reactions and social and sexual behaviour, as well as 
regulating the sense of smell. 
 
MEMORY 
 
 Memory is the ability of an individual to record sensory stimuli, events, 
information etc., retain them over short or long periods of time and recall the same at a 
later date when needed. Poor memory, lower retention and slow recall are common 
problems in today’s stressful and competitive world. Age, stress and emotions are 
conditions that may lead to memory loss.  
Memory is the process in which information is encoded, stored and retrieved. 
Encoding allows information from the outside world to be sensed in the form of chemical 
and physical stimuli. In the first stage the information must be changed so that it may be 
put into the encoding process. Storage is the second memory stage or process. 
 This entails that information is maintained over short periods of time. Finally the 
third process is the retrieval of information that has been stored. Such information must be 
located and returned to the consciousness. Some retrieval attempts may be effortless due 
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to the type of information, and other attempts to remember stored information may be 
more demanding for various reasons. 
From an information processing perspective there are three main stages in the formation 
and retrieval of memory: 
• Encoding or registration:  Receiving, processing and combining of received 
information 
• Storage: Creation of a permanent record of the encoded information in short term or 
long term memory. 
• Retrieval, recall or recollection: Calling back the stored information in response to 
some cue for use in a process or activity 
The loss of memory is described as forgetfulness. 
Poor memory, lower retention and slow recall are common problems in today’s stressful 
and competitive world. Age, stress emotion re conditions that may lead to memory loss26. 
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LEARNING:  
Learning is a process of acquisition of information based on events occurring around and 
same is called memory. It influences thinking, planning particularly decision making.  
Acquisition and storage of information enable the organism to repeat successfully and to 
avoid failures by utilizing its past experience.  
There are two types of learning 
• Active learning  
• Passive learning 
Active learning: It exerts a considerable degree of voluntary control over the learning 
process and the gradual diminution of response to a specific stimulus, which is given 
several times called habituation. 
Passive learning: It is regarded as a hobby or more for fun as it is not the optimal learning 
style. It allows the freedom to think clearer.   
Learning and Memory are closely related, all learning involves memory but all memory 
need not involve to learning27.  
MEMORY DISORDERS: 
  It results due to damage of neuroanatomical structures that hinders the storage, 
retention and recollection of memories. Memory disorders can be progressive including 
Alzheimer’s disease or they can be immediate including disorders resulting from head 
injury.  
Memory disorders include: Alzheimer’s disease, Agnosia, Amnesia, Brain injury, 
Dementia, Huntington’s disease, Parkinson’s disease, stress, Wernicke-Korsakoff’s 
syndrome.   
Aging: Although normal aging is not responsible for memory associated disorder. It is 
associated with a decline in cognitive and neural systems including memory. Many factors 
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such as genetics and neural degeneration have a part in causing memory disorder. Plaques 
and tangle deposits are found with aging. 
Beta amyloid protein deposit in brain is called as the key marker to diagnose Alzheimer’s 
and Dementia. 20-30% of healthy adult has found to have beta amyloid deposits. 
Additionally, traumatic brain injury, TBI, is increasingly being linked as a factor in early-
onset Alzheimer’s disease28. 
Agnosia:  Inability to recognize certain objects, persons or sounds, yet there are many 
more specific diagnoses of agnosia. Agnosia is typically caused by damage to the brain 
(most commonly in the occipital or parietal lobes) or from a neurological disorder29.  
Huntington’s disease.  
An inherited progressive disorder of the brain that leads to uncontrolled 
movements, emotional instability, and loss of intellectual faculties.29 Because of the 
inheritability of Huntington's each child born to a parent with Huntington's has a 50% 
chance of inheriting the disease, leading to a prevalence of almost 1 in 10,000 Canadians 
(0.01%).30 
Dementia:  
Dementia refers to a large class of disorders characterized by progressive 
deterioration of thinking ability and memory as the brain becomes damaged. It can be 
categorized as reversible (e.g. thyroid disease) or irreversible (e.g. Alzheimer's disease).31 
Currently, there are more than 35 million people with dementia worldwide. In the United 
States alone the number of people affected by dementia is striking at 3.8 million.32 
Dementia is an acquired syndrome of decline in memory and atleast one other cognitive 
domain, such as language, visio-spatial or executive function that is sufficient to interfere 
with the social or occupational function in an alert person33. They majorly affects memory, 
attention, Language and problem solving. Alzheimer’s or Alzheimer disease  accounts for  
about 60 to 70%  of cases of dementia. It is a chronic neurodegenerative disease that 
usually starts slowly and gets worse over time34-35.  
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ALZHEIMER'S DISEASE 
Alzheimer's disease (AD) is a progressive, degenerative and fatal brain disease, in which 
cell to cell connections in the brain are lost. Alzheimer's disease is the most common form 
of dementia.36 Globally approximately 1-5% of the population is affected by Alzheimer's 
disease.37 Women are disproportionately the victims of Alzheimer’s disease, with 
evidence suggesting that women with AD display more severe cognitive impairment 
relative to age-matched males with AD, as well as a more rapid rate of cognitive decline.38 
Origin: 
Alzheimer is a peculiar disease of cerebral cortex identified by Dr. Alios Alzheimer in 
1906 and was later named as Alzheimer’s disease39.   
Alzheimer’s disease is characterized by increasing loss of memory and cognitive function 
and at an anatomical level, by plaques of a protein called amyloid and by neurofibrillary 
tangles40. It is described as thin cortex speckled with usual brown clumps and irregular 
knots that was found to be growing inside the brain cells and are now known as amyloid 
plaques and neurofibrillary tangles.   
Brains of people with AD have been found to have abundant of two abnormal structures. 
Amyloid plagues and neurofibrillary tangles which are made of misfolded proteins. 
Diagnosed in both the gender over 65 years of age41. The symptoms of Alzheimer’s 
disease are unique for every individual42.   
Assesment 
AD is diagnosis confirmed with behavioral assessments, cognitive tests and followed by 
brain scan43. Recently researchers have found that activity-dependent neuroprotective 
protein (ADNP) in elderly individuals can assess the patients at risk for Alzheimer's 
disease. ANDP levels in blood and amyloid plaques (a hallmark Alzheimer's) in the 
brain," said lead researcher Illana Gozes from Tel Aviv University in Israel. 
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Fig 4: Comparison of Normal and Alzheimer’s neuron 
 
Fig 5: Comparison of Normal and Alzheimer’s brain 
 
HYPOTHESIS OF THE DISEASE 
Several biochemical and pathological mechanism contribute to AD. These include 
Amyloid hypothesis:44-45  
Imbalance in production of amyloid β (Aβ) vs its clearance resulting in 
accumulation of Aβ in the form of senile plaques. Those plaques can induce 
neuroinflammatory process and trigger the production reactive oxygen species. 
Cholinergic hypothesis46 
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  Cholinergic deficits resulting due to enhanced activity of acetyl cholinesterase and 
Butyl cholinesterase, contributing to the cognitive impairments seen in AD.  
Tau Hypothesis47:  
Neurons have an internal support structure partly made up of microtubules. 
A protein called tau helps to stabilize these microtubules. In Alzheimer's disease, 
tau produces change in microtubules to collapse, devastate and clump the neural active 
proteins together to form neurofibrillary tangles and senile plaques. 
Based on those hypotheses several anti amyloid48 and cholinesterase inhibitors49 are 
investigated for their disease modifying strategies. 
 
Stages of Alzheimer50: 
 
Fig 6: Stages of Alzheimer 
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Changes in brain due to Alzheimer’s 
 
 
 
 
 
Fig 7: Changes in brain due to Alzheimer.  
Alzheimer’s disease leads to nerve cell death and tissue loss throughout the brain. 
Over time, the brain shrinks dramatically, affecting nearly all its functions.  
Causes of Alzheimer51-52 
¾ Scientist believes that Alzheimer’s are main caused due to combination of 
genetic, life style and environmental factors that affect the brain over time.  
¾ Less than 5% of Alzheimer’s  is caused by specific genetic changes that 
virtually guarantee a person to Alzheimer’s 
¾ Causes of Alzheimer are still not clearly understood.  
¾ Person suffering from Alzheimer has many fewer cells in brain and very fewer 
connections among the surviving cells. 
¾ Medications:  Includes antidepressants, antihistamines, anti-anxiety 
medications, muscle relaxants, tranquilizers, sleeping pills, and pain 
medications given after surgery. 
¾ Alcohol, tobacco or drug use 
¾ Sleep deprivation: Both quantity and quality of sleep are important to 
memory. 
¾ Depression and stress: Being depressed and stressed can make it difficult to 
pay attention and focus, which can affect memory. Stress and anxiety can also 
get in the way of concentration.  
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¾ Nutritional deficiency: Good nutrition, including high-quality proteins and 
fats are important for proper brain function. Deficiencies in vitamin B1 and B12 
specifically can affect memory. 
¾ Head injury: A severe hit to the head, from a fall or automobile accident, can 
injure the brain and cause both short- and long-term memory loss. Memory 
may gradually improve over time. 
¾ Stroke: A stroke occurs when the blood supply to the brain is stopped due to 
the blockage of a blood vessel to the brain or leakage of a vessel into the brain. 
¾ Dementia: Dementia is the name for progressive loss of memory and other 
aspects of thinking that are severe enough to interfere with the ability to 
function in daily activities. Although there are many causes of dementia, 
including blood vessel disease, drug or alcohol abuse, or other causes of 
damage to the brain, the most common and familiar is Alzheimer's disease. 
Alzheimer's disease is characterized by a progressive loss of brain cells and 
other irregularities of the brain. 
¾ Other causes: Other possible causes of memory loss include an underactive or 
overactive thyroid gland and infections such as HIV, tuberculosis, and syphilis 
that affects the brain. 
Risk factors:  
¾ Age- The greatest risk, risk increases greatly after reaching the age of 65. 
¾ Family history- Risk of developing Alzheimer’s appears to be somewhat 
higher if a first-degree relatives has the disease. Occurs only among 5 % of 
Alzheimer cases. 
¾ Down syndrome: Signs and symptoms of Alzheimer’s tends to appear 10 to 20 
years earlier in the people with Down’s Syndrome than they do in general 
population. A gene contained in the extra chromosome that causes Down’s 
syndrome significantly increases the risk of Alzheimer’s disease. 
¾ Sex: Women seems to be more likely to develop Alzheimer than Men.  
¾ Mild cognitive impairment: People with mild cognitive impairment have an 
increased risk of Alzheimer’s.  
¾ Past head trauma: People who had a severe head trauma are more likely to 
have Alzheimer’s. 
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¾ Life style and heart health: There’s no lifestyle factor that’s been definitely 
shown to reduce your risk of Alzheimer’s disease. 
¾ Miscellaneous: Lack of exercise, obesity, smoking or exposure to second hand 
smoke, High blood pressure, High blood cholesterol, Poorly controlled type II 
diabetes, diet lacking fruits and vegetables. 
 
Signs and symptoms: 
 Memory impairment, Difficult concentrating, planning or solving problem, 
Problem in finishing daily tasks, confusion with location or passage of time, misplacing 
items, language problem, using poor judgment and decisions. Withdrawal from work 
events or social engagements. Change in moods, such as depression or other behavior and 
personality changes.  
 
Diagnosis of Alzheimer:  
Having trouble with thinking does not mean that a person has Alzheimer. Many health 
issues may cause problem with memory and thinking.  
Diagnosing Alzheimer requires careful medical evaluation,  which includes 
A through medical history, Mental status testing, A physical and neurological exam, Tests 
(such as blood tests and brain imaging) to rule out other causes of dementia-like 
symptoms. 
 
The disease can be diagnosed post mortem by observing tangles inside and senile plaques 
outside cells throughout the brain53 
Treatment:  
Two types of treatment are currently in use to treat cognitive symptoms. 
Cholinesterase inhibitors: These drugs work by boosting cell to cell communication by 
providing a neurotransmitter (acetylcholine) that is depleted in the brain by Alzheimer’s 
disease. The improvement is modest. Cholinesterase inhibitor can improve 
neuropsychiatric symptoms, such as agitation or depression, as well. 
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The US FDA approved drugs include  Eg: Donepezil, Galantamine, and 
Rivastigmine.54-55 
Side effect: Diarrohea, nausea, loss of appetite, Sleep disturbance, The main serious side 
effects may include a slow heart rate and heart block in people with cardiac conduction 
disorder56-60. 
Memantine: The drug works in another brain cell communication network and slows the 
progression of symptoms with moderate to severe Alzheimer’s disease.  Some time given 
in combination with Cholinesterase inhibitors. 
Side effect: Constipation, Dizziness and head ache. 
STATISTICS OF ALZHEIMER:  
WHO has reported that 5% of men and 6% of women of above the age of 60 years are 
affected with Alzheimer’s type dementia61. WHO has estimated 35.6 million people are 
currently living with dementia worldwide which is expected to increase by 65.7 million by 
2030 and 115.4 million by205062.  Alzheimer's is predicted to affect 1 in 85 people 
globally by 205063. 
Recent figures of 2015 reported that almost two thirds of Americans with Alzheimer’s 
disease are women.1 in 3 seniors dies with Alzheimer or dementia. 6th leading cause death 
in the United States.  
NEED FOR NATURAL SOURCES AS ANTI-ALZHEIMER AGENT 
Due to various side effects that are observed in the synthetic drugs the human population 
is now moving towards the natural source in search of remedies for Alzheimer’s disease. 
There are over 1.5 million practitioners of traditional medicinal system using medicinal 
plants in preventive, promotional and curative applications 
 
HERBAL REMEDIES FOR ALZHEIMER 
Herbal remedies for Alzheimer disease have become more and more popular in the 
recent years. It has not happened without any reason but the possibility to slow down the 
brain’s degeneration caused by Alzheimer is more than conventional drug. Thus natural 
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treatment has drawn the attention of the scientific community.  Many natural herbal 
treatments have been researched and the benefits have been derived for the used herbs in 
the treatments of Alzheimer disease and dementia. Thus herbs are used in the present 
study for the treatment of Alzheimer. In addition, these herbs are inexpensive and can be 
easily obtained which makes researchers to bend towards the plant source for the treatment 
of Acute and Chronic diseases64.   
 Table No 1. Herbs used for treatment of memory disorders (64-69) 
S.NO BIOLOGICAL NAME SYNONYM 
ACTIVE 
CONSTITUENTS 
1. Baccopa monnieri Brahmi Triterpene glycoside 
2. Valriana wallichi Tagara Flavones glycoside 
3. Nardostachys jatamansi Jatamansi Flavonoids 
4. Withania somnifera Ashwaganda Withenolides 
5. Terminalia arjuna Arjuna Alkaloids 
6. Piper longum Pippali moola Alkaloids 
7. Myristica fragrance Jatiphala Volatile oil 
8. Acorous calamus Vacha Phenolic compounds 
9. Rauwolfia serpentine Sarpagandha Alkaloids 
10. Celastrus paniculatus Jyothismati Volatile oil. 
11 Boswellia serrata Shallaki Boswellic acid 
12 Curcuma longa Haldi Curcumin 
13 Ginkgo biloba Maidenhair tree Flavonoid glycoside, 
Ginkgolide B 
14 Ficus carica Fig plant Quercetin 
(Flavonoids) 
15 Ficus religiosa Peepul tree Amino acids 
16 Citrus sinensis Orange Polymethoxy 
flavones 
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Fig 8: Plants used in treatment of Alzheimer’s disease 
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Drugs used for Alzheimer’s which contain isolated plant constituents (70-71) 
Huperizine A is an alkaloid with a potent acetyl cholinesterase inhibitory activity isolated 
from the Chinese club moss Huperzia serrata. Huperizine A is currently available in the 
USA as “Nutraceuticals” or “functional food”. 
Galantamine is an alkaloid used for symptomatic treatment of patients with early onset 
Alzheimer’s disease. It was initially isolated from the snowdrop (Galanthus woronowii) in 
the early 1950’s and has since been found in other plants in the family Amaryllidaceae. 
Galantamine slows the process of neurological degeneration by inhibiting AchE. Due to 
the limited availability of the plants of origin of this compound, Galantamine is now 
produced by total synthesis. 
Considering the importance of herbal medicine in memory strengthening activity, the 
present study was aimed to investigate the effects of Citrus maxima fruit peel containing 
large amount of flavonoids which has been reviewed to have potential to treat Alzheimer. 
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2. ETHNO BOTANICAL SURVEY 
PLANT PROFILE72  
Plant name : Citrus maxima (J. Burm.) Merr.. 
Common name :  Pomelo, Pommelo, Jabong, Shaddock, Chinese fruit, etc 
Tamil name :  Pambalimasu 
Family :  Rutaceae 
VERNACULAR NAMES73 
Hindi  : Sadaphal, बतावी नीबू Batawi nimbu, चकोतरा Cakotaraa  
Manipuri  : Nobab  
Tamil  : Pambalimasu  
Malayalam  : Pamparamasan  
Telugu  : Pampara  
Bengali  : Chakotra  
Konkani  : Toranji  
Sanskrit  : Madhukarkati  
French  : Pamplemmousse  
German  : Pomelo  
Taxonomy of plant:   
Botanical name  :Citrus maxima (J.Burm.)Merr. 
Taxanomical Classification 
Kingdom : Plantae 
Phylum : Tracheophyta 
Division : Magnoliophyta 
Class : Magnoliopsida 
Order : Sapindales 
Family  : Rutaceae 
Sub family : Aurantioideae 
Genus : Citrus  
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Species  : maxima  
Habit And Habitat72: Tree of 16-50 ft (5-15 m) tall, with somewhat crooked trunk of 4-12 
inches. North eastern region up to 1,500 m in Assam and Tirupura. It is indigenous to East of 
India.  
 
Fig 9: Whole plant Citrus maxima 
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Fig 10: Fruits of Citrus maxima 
 
Fig 11: Fruits on tree of Citrus maxima 
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Fig 12: Leaves of Citrus maxima  Fig 13: Seeds of Citrus maxima 
 
Fig 14: Flower, and fruits of Citrus maxima 
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Fig 15:  Fruit and Pulp of Citrus maxima. 
PLANT DESCRIPTION: 
Citrus maxima are a perennial shrub commonly known as Papanus, distributed throughout 
India.  
MORPHOLOGY74-76:  
Leaves : Large evergreen oblong to elliptic leaves, 10.5 to 20 cm (4 to 8 in) long.    
   Frequently emarginated, Pubescent beneath. Acute apex, Asymmetric  
  base, entire margin, characteristic odour 
Petioles  : Broadly winged 
Flowers : Large, White 
Stamens  : 16-24 
Fruit : Large, pale yellow, globose or pyriform, rind thick, pulp varying in   
  colour from crimson to pale pink to yellow 
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ETHANOBOTANICAL USES72   
Leaves : Epilepsy, Cholera, Convulsive cough and also in the treatment of  
  hemorrhage disease. Oil from fresh leaves posses anti dermatophytic  
  activity and Fungicidal activity. 
Flower : Used as sedative in nervous affection 
Fruits : Leprosy, Asthma, Cough, Hiccough, Mental aberration, Epilepsy,  
  cardiotonic. 
Rind : Antiasthmatic, sedative in nervous affection, Brain tonic, Useful in  
  Vomiting, griping of abdomen, diarrhea, Headache and eye troubles.  
Roots & 
Bark 
: Antimicrobial activity. 
 
PHYTOCONSTITUENTS PRESENT IN PLANTS OF Citrus maxima 
Alkaloids 
 
 
 
: 5-hydroxyacronycine, acriginine A, Atalafoline, Baiyumine A & B, 
Buntanine,  Buntanmine, Grandisine I & II, Pumiline, honyumine, 
natsucrin, Prenyl citpressine, Citropone A & B, Glycocitrine I are present in 
the roots and the bark of the plant. Caffeine are present in the flowers of the 
Citrus maxima 77-82.  
Amino Acids: 
 
: Alanine, Asparigine, Aspartic acid, Coline, Glutamic acid, Glycine And 
proline are present in the leaves 83, 84. 
 Carbohydrates 
 
: Phytol, Synephrine, Methyl antralinate, Fructose, Glucose and Pectin are 
present  in the Leaf, peel and flowers 85-89.  
Carotenoids: : Carotene90  and Roseoside 91 present in the peels.  
Coumarins: 
 
 
: 5-Geranoxy-7-methoxy-Coumarin, Aurapte, Auraptene, bergamottin 92-94 
are present in the peels and 5-methoxy seselin, 5-methyltodannol, 6-hydroxy  
methylherniarin are present in the roots and stem bark.  
Flavonoids: 
 
: Acacetin, rutin, tangeretin, cosmosiin, diosmetin, diosmin, eriocitrin, 
hespeidin,  naringin 95.  
Monoterpenes: 
 
: α-pinene, α-terpineol, anethole, β-pinene, Camphene, camphor, citral,  
citronellal, citroonellol, farnesol, geraniol, myrcene, neral, terpinene 96. 
Sesquiterpenes: : α-Bisabolol, α-cadinene, α-copaene, elemol.  
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Miscellaneous: 
 
: α- tocopherol, ascorbic acid, chlorophylls, decyl acetate, Malonic acid, 
Fumaric acid, succinic acid and Citric acid . 
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3. REVIEW OF LITERATURE  
 
3.1. PHARMACOGNOSTICAL REVIEW 
1. Kharjul, Aswini  et. al., (2012 ) performed Pharmacognostic investigation On 
leaves of Citrus maxima as per WHO guidelines97.  
2. Pandya Devang et. al., (2011) performed pharmacognostic and phytochemical 
characterization of leaves of Citrus maxima as per WHO guidelines98. 
3.2. PHYTOCHEMICAL REVIEW  
1. Shourie  Abhilasha., (2014) performed  ultrasonication assisted extraction of 
phenolic antioxidants from Citrus maxima leaves and their GC-MS profile99.  
2. Aimee Sheree A. Barrion et. al., (2014) determined phytochemical Composition, 
Antioxidant and Antibacterial Properties of Pummelo (Citrus maxima (Burm.)) 
Merr. against Escherichia coli and Salmonella typhimurium100. 
3. Pandya Devang et. al., (2011) determined both pharmacognostic and 
phytochemical characterization of leaves of Citrus maxima98.  
3.3.  PHARMACOLOGICAL REVIEW 
1. Mohammed Riaz Hasan Chowdhury et. al., (2015) used supplementation Of Citrus 
maxima peel powder to prevent oxidative stress, fibrosis, and hepatic damage in 
carbon tetrachloride (CCl4) treated rats101.  
2. Abdul Muneer Mt et. al., (2014 ) evaluated the anti-diabetic activity of ethanolic 
extract Of Citrus maxima Stem Bark on alloxan and streptozotocin induced 
diabetes in Wistar rats102.  
3. Haja Sherief Sheik et. al., (2014) evaluated Central Nervous System activities Of 
Citrus maxima leaf extract on rodents the depressant, anxiolytic, convulsant, 
hypnotic and muscle relaxants were performed on the experimental animals103. 
4. Ganiyu Oboh et. al., (2014) studied hypocholesterolemic properties of grapefruit 
(Citrus paradisii) and shaddock (Citrus maxima) juices and inhibition of 
Angiotensin-1-converting enzyme activity where angiotensin-1-converting enzyme 
(ACE) activity in vitro and the hypocholesterolemic properties of the juices in rats 
fed a high-cholesterol diet104. 
5. Shivananda A (2013) determined the analgesic and anti-Inflammatory activities of 
Citrus maxima (J.Burm) Merr. in animal models105. 
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6. A.Oyedepot  and S.O. Babarinde (2013) studied the effects of Shaddock (Citrus 
maxima) fruit juice on glucose tolerance and lipid profile in type-ii in 
streptozotocin (STZ) induced type-II diabetic rat 106. 
7. Oyedepo, T. A. (2012) studied the antioxidant potential of Citrus maxima fruit 
juice in rats107. 
8. Vikram H et. al., (2011) evaluated the antidepressant-like effect of Citrus maxima 
leaves in animal models of depression108. 
9. Sriparna kundunsen (2011) assessed the antitumor activity Of Citrus 
maxima (Burm.) Merr. leaves in ehrlich's ascites carcinoma cell-treated mice109. 
10.  Kundusen et. al (2011) explorated the anti-inflammatory potential Of Citrus 
limetta Risso And Citrus maxima (J. Burm.) Merr in histamine, carrageenan and 
dextran induced acute rat paw oedema models in Wistar albino rats110. 
11.  Sriparna Kundusen et. al., (2011) explorated of in vivo antioxidant potential Of 
Citrus maxima leaves against Paracetamol induced hepatotoxicity in rats111. 
12.  Kundusen et. al., (2010) evaluated in vitro antioxidant activity of methanolic 
extract of  Citrus limetta fruit peel And Citrus maxima leaves on reactive oxygen 
and nitrogen species and inhibition of lipid peroxidation. The total phenolic 
compounds present in the extracts were also estimated by Folin-Ciocalteu’s 
reagent112. 
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4. RATIONALE FOR SELECTION72:  
 
¾ Most of the plants are used by validating the traditional claims. There are various 
plants yet to be verified.  
¾ Citrus maxima is one such fascinating shrub of family Rutaceae. It is commonly 
known as Papanus, Pommelo, shaddock, etc.  
¾ The plant has a long history of numerous traditional and ethno botanical 
applications in diverse cultures. Many tribes considered it as a cure for all ailments. 
• Leaves: Epilepsy, chorea, Convulsive cough and also in the treatment of 
hemorrhage disease. Oil from fresh leaves posses anti dermatophytic 
activity, Fungicidal activity. 
• Flower: Used as sedative in nervous affection 
• Fruits: Leprosy, Asthma, Cough, hiccough, mental aberration, Epilepsy, 
cardiotonic. 
• Rind: Antiasthmatic, sedative in nervous affection, Brain tonic, Useful in 
vomiting, griping of abdomen, diarrhea, Headache and eye troubles.  
• Root and Bark: Antimicrobial activity. 
 
¾ Present study deals with the evaluation of the Peels of Citrus maxima which is 
claimed to be brain tonic thus it is being studied for anti Alzheimer activity, 
which was not scientifically evaluated earlier.  
¾ No pharmacognostical work has been carried out on the peels so far. 
¾ The Anti Alzheimer  activity was not scientifically validated. 
 
So the fruit peels of the plant Citrus maxima, was selected for evaluation of anti-
Alzheimer activity. 
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5. AIM AND OBJECTIVE OF THE STUDY 
5.1. AIM 
In the present study an attempt was made  
¾ To standardize the peels of Citrus maxima (J. Burm.) Merr by carrying out 
Pharmacognostical and Phytochemical studies. 
¾ To carry out in-vitro anti oxidant and   -Acetylcholinesterase activity for the 
selection of the active extract. 
¾ To evaluate the anti Alzheimer activity of the peels of the fruit Citrus maxima 
using  Morris water maze method and Radial Y maze  
¾ To isolate the active compound from the selected extract and to perform the 
insilico docking using Argus lab.    
 
5.2 . OBJECTIVE 
Research and extension work are the key to intergrate folk medicine into primary health 
care. The major objective is to bring safe, effective remedies to common illness, using 
local medicinal plants. In this modern era, a large Indian population still relies on the 
traditional system of medicine, which is mostly plant based. One such plant is Citrus 
maxima (J. Burm.) Merr (Rutaceae). The main objective of the present work is 
pharmacognostical identification of plant, isolation of active constituents, phytochemical 
screening and pharmacological activity of the selected plant. 
 
Plan of work 
 
Department Of Pharmacognosy, COP, MMC, Chennai-03 Page 35 
 
6. PLAN OF WORK 
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7. MATERIALS AND METHODS 
Plant Collection and Authentication  
Fresh fruits were collected from Cuddalore, Tamil Nadu, authenticated by Dr. 
G.V.S. Murthy, Scientist “F” and Head of Office, Botanical Survey of India, Southern 
Regional Centre, T.N.A.U campus, Lawley road Coimbatore- 641003. A specimen copy 
of the Herbarium is placed in the Department of Pharmacognosy with Voucher No:  
18/PCOG/2015.  The Peels of fruit Citrus maxima were separated and shade dried, cut into 
pieces, powdered and was stored in the air tight container. 
 7.1. PHARMACOGNOSTICAL STUDIES  
Pharmacognostical study is the preliminary step in the standardization of crude 
drugs. It primarily deals with the identification, authentication and standardization of 
herbal medicinal plants through organoleptic character, histological character, powder 
microscopy, quantitative microscopy, histochemical analysis and physio chemical 
observations as prescribed by an authoritative source such as World Health Organization 
(WHO)113--114. 
 Evaluation of crude drug involves determination of authenticity, quality, purity, 
potency, safety, efficacy, reliability and reproducibility of the evaluation results for 
varying batch of crude drug. This is also used in the detection of nature of adulteration. 
Systematic identification of crude drugs and their quality assurance gives an integral part 
of drug description. 
MACROSCOPY  
 Macroscopical characters includes organoleptic characters and morphological 
features of the plant were studied. These observations are of primary importance before 
any further testing can be carried out115. 
MICROSCOPY  
Staining method 
 Fixation of plant organ – The peels was cut, fixed in FAA solution (Formalin 5ml 
+ Acetic acid 5ml + 90ml of 70% Ethanol). The specimen was dehydrated after 24 hours 
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of fixing. The seeds were graded with series of tertiary butyl alcohol, as per the standard 
method116. 
            Infiltration of the specimen - It was carried out by gradual addition of 58 – 60º C 
of melting pointed paraffin wax until Tertiary butyl alcohol (TBA) solution attained super 
saturation. The specimens were cast into paraffin blocks117. 
Sectioning  
 The paraffin embedded specimens were sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10 - 12µg. Dewaxing of the sections were 
done by customary procedures. The sections were stained with Toludine blue. Since 
toludine blue,  is a polychromatic stain, the staining results were remarkably good. The 
dye rendered pink colour to the cellulose walls, blue to the lignified cells, dark green to 
subrein, violet to mucilage and blue to the protein bodies. Whenever necessary sections 
were also stained with safranin, fast green and iodine for starch118.  
PHOTO MICROGRAPHS 
 Microscopic descriptions of tissues were supplemented with photo micrographs 
whenever necessary. Photographs of different magnifications were taken with Samsung 
Camera. For normal observations bright field was used. 
  For the study of crystals and lignified cells, polarized light was employed. Since, 
these structures have birefringent property under polarized light they appear bright against 
dark background. Descriptive terms of the anatomical features are as given in the standard 
anatomy books. 
POWDER MICROSCOPY 119 
  The shade dried, powdered plant material was used for powder microscopic 
analysis. The organoleptic characters were observed and to identify the different 
characteristic features various staining reagent were used. Powder was stained with 1% 
phloroglucinol in 90% ethanol, concentrated hydrochloric acid and observed through 
microscope. All the lignified cells stained with pink colour. Calcium oxalate crystals were 
observed under the polarized light microscope Magnus MLX (220-240 V) Manufactured 
by Olympus opto systems India Pvt Ltd.Noida.    
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HISTOCHEMICAL STUDIES120  
Portions of fresh fruit peels of the plant of Citrus maxima Burm., were used. The 
peels were soaked in water before taking the sections. The sections were stained using 
specific reagents ( N/50 iodine, dilute ferric chloride, phloroglucinol and Conc. 
hydrochloric acid, picric acid, ortho toludine blue and dragendroff reagent) to observe and 
locate starch, tannin,lignin, protein, flavonoid and alkaloid respectively as per the 
protocols. The stained sections were then washed in water to remove the excess stain and 
observed under a microscope Magnus MLX (220-240 V).  Manufactured by Olympus opto 
systems India Pvt Ltd.Noida.  
PHYSIO-CHEMICAL CONSTANTS121-123 
 Shade dried powdered plant materials of  the fruits of Citrus maxima was used for 
the determination of the physio chemical constants in accordance with the WHO 
guidelines. 
DETRMINATION OF ASH VALUES 
 Ash values are helpful in determining the quality and purity of a crude drug in the 
powdered form. The residue remaining after incarnation is the ash content of the drug, 
which simply represents inorganic salts, naturally occurring in the drug or adhering to it or 
delibility added to it, as a form of adulteration. 
 Ash value of a crude drug is defined as the inorganic residue remaining after 
incineration, which complies of inorganic salts, naturally occurring in drug or adhering to 
it or deliberately added to it as a form of adulteration. Hence it is used for the 
determination of the quality and purity of the crude drug in the powdered form.  
TOTAL ASH 
 Total ash method is designed to measure the total amount of material remaining 
after ignition.  They include both physiological ash which is derived from plant tissue 
itself and non-physiological ash which is the residue of extraneous matter adhering to the 
plant surface. 
Procedure:  
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 Silica crucible was heated to red hot for 30 minutes and cooled in the desiccators 
Incinerate about 2 to 3 g accurately weighed, powered drug in a tarred silica dish at a 
temperature not exceeding 4500C until the sample is free from carbon, cooled in 
desiccators and weighed. The ash obtained was weighed. The percentage of total ash was 
calculated.  
WATER SOLUBLE ASH: 
The difference in weight between the total ash and the residue after treatment of the total 
ash in water.  
Procedure: 
 Total ash obtained is boiled for 5 minutes with 25 ml of water, insoluble matter 
were collected in a ashless filter paper, washed with hot water and ignited for 15 min at a 
temperature not exceeding 4500C. The weight of this residue in mg was subtracted from 
the weight of total ash. The content of water-soluble ash in mg per gram of air-dried 
material was then calculated 
   Water soluble ash =  Weight of residue obtained    X 100 
      Weight of the sample taken  
ACID INSOLUBLE ASH: 
 The residue obtained after boiling the total ash with dilute hydrochloric acid, the 
remaining insoluble matters are ignited and measured. This measures the amount of silica 
present, especially as sand and siliceous earth.  
Procedure:  
 To the crucible containing total ash of the sample, 25 ml of dilute hydrochloric 
acid is added. The insoluble matter is collected on an ashless filter paper (Whatman 41) 
and washed with hot water until the filtrate is neutral.  Filter paper containing the insoluble 
matter was then transferred to the crucible, dried on the hot plate and ignited to constant 
weight. The residue was cooled in a suitable desiccators for 30 minutes and weighed 
without delay. Content of acid-insoluble ash with reference to the air dried drug is 
calculated. 
  Acid insoluble ash =  Weight of the residue obtained    X 100 
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     Weight of the sample taken  
SULPHATED ASH 
 Sulphated ash test is used to measure the amount of residual substance not 
volatilized from a sample. These test are usually used to determine the content of 
inorganic substance.  
Procedure:  
 Silica crucible was heated to redness for 10 minutes, allowed to cool in a 
desiccator and weighed. 2 g of sample was accurately weighed, ignited gently then 
thoroughly chared. Cooled, moistened the residue with 1 ml of sulphuric acid, heated 
gently until the white fumes are no longer evolved and ignited at 800 ± 25o C until all 
black particles have disappeared. Crucible are allowed to cool,  few drops of sulphuric 
acid was added and heated. Ignite as before, allow to cool and weigh. This process is 
repeated until two successive weighing differ by more than 0.5 mg.  
 
DETERMINATION OF EXTRACTIVE VALUES: 
 Extractive values are useful for the evaluation of phytoconstituents especially 
when the constituents of a drug cannot be readily estimated by any other means. Further 
these values indicate the nature of the active constituents present in a crude drug. 
Determination of water soluble extractive 
                     5gm of air dried coarsely powdered sample was weighed and macerated with 
100ml of chloroform water (95ml distilled water and 5ml chloroform) in a closed flask for 
24 hours. It was shaken frequently for six hours and allowed to stand for rest eighteen 
hours. It was then filtered rapidly taking precautions against loss of solvent and 25ml of 
the filtrate was evaporated to dryness in a tarred flat bottomed shallow dish and was dried 
at 105°C for 1 hour in the hot air oven and cooled in desiccators for 30min and weighed. 
The process was repeated till a constant weight was obtained; the percentage of water 
soluble extractive value was calculated with reference to the air dried drug. 
    Water soluble extractive value =  Weight of the dried extract   X   100 
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 Weight of the sample taken 
Determination of alcohol soluble extractive 
                           5gm of the coarsely powdered sample was weighed and macerated with 
100ml 90% ethanol in a closed flask for 24 hours. It was shaken frequently for six hours 
and allowed to stand for eighteen hours. It was then filtered rapidly, taking precautions 
against loss of solvent and 25ml of the filtrate was evaporated to dryness in a tarred flat 
bottomed shallow dish. It was dried at 105°C for 1hour in a hot air oven. The dish was 
cooled in desiccator and weighed. The process was repeated till the constant weight was 
obtained. The percentage of alcohol soluble extractive value with reference to the air dried 
drug was calculated. 
 Determination of non volatile ether soluble extractive (fixed oil content) 
                     A suitably weighed quantity of the sample was transferred to an extraction 
thimble and extracted with solvent ether or petroleum ether (Boiling Point 40 - 60°C) in a 
Soxhlet for 6 hours. The extract was filtered into a tarred evaporating dish, evaporated and 
dried at 105°C to constant weight. The percentage of non volatile ether soluble extractive 
value with reference to the air dried drug was calculated.  
Determination of volatile ether soluble extractive 
                     2gm of powdered sample was accurately weighed and extracted with 
anhydrous diethyl ether in a continuous extractive apparatus for 20hours. The ether 
solution was transferred to tarred porcelain dish and evaporated spontaneously, dried over 
phosphorous pent oxide for 18hours and the total ether extract was weighed. The extract 
was heated gradually and dried at 105°C to constant weight. The loss in weight represents 
the volatile portion of the extract. 
 Volatile ether soluble extractive=  Weight of the dried extract X  100 
      Weight of the sample taken 
DETERMINATION OF LOSS ON DRYING: 
Loss on drying 
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                   10 g of the sample substances (without preliminary drying) was taken in a 
tarred evaporating dish.  Use of high speed mill in preparing the samples are avoided. The 
sample in the tarred evaporating dish was placed in the drying chamber (105°C) for 5 
hours and weighed. Drying and weighing is continued every one hour interval until the 
difference between the two successive weight is not more than 0.25 percent. Constant 
weight is reached when the two consecutive weighing after drying for 30 minutes and 
cooling for 30 minutes in a desiccators, show not more than 0.001 g difference. Percentage 
loss on drying and was calculated with respect to the air dried sample. 
 % Loss on drying =  Final weight of the sample X  100 
     Initial weight of the sample 
Determination of foaming index 
                    1gm of the coarsely powdered drug was weighed and transferred to 500ml 
conical flask containing 100ml boiling water. The flask was maintained at temperature 80-
90°C for about 30min. It was then cooled and filtered into a volumetric flask and sufficient 
water was added through the filtrate to make up the volume to 100ml. The decoction was 
poured into 10 stopper test tube (height 16cm, diameter 16mm) in successive portions of 
1ml, 2ml, 3ml, 4ml up to 10ml and the volume of the liquid in each tube was adjusted with 
water to 10ml. The tubes were stoppered and shaken in a length wise motion for 15 
seconds, two shakes per second. Allowed to stand for 15min and the height of the foam 
was measured. The results are assessed as follows. 
                    If the height of the foam in every tube is less than 1cm, the foaming index is 
less than   100. If a height of 1cm is measured in any tube, the volume of the plant material 
decoction in the tube (a) is used to determine the index. If this tube is the first or second 
tube in a series, prepare an intermediate dilution in a similar manner to obtain a more 
precise result. 
                    If the height of the foam is more than 1cm in every tube, the foaming index is 
over 1000. In this case repeat the determination using a new series of dilution of the 
decoction in order to obtain a result. Calculate the foaming index using the following 
formula: 
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                                      Foaming index = 1000/a 
     Where, a = the volume in ml of the decoction used for preparing the dilution in the tube 
where foaming to a height of 1cm is observed. 
Determination of swelling index  
                  The swelling index is the volume in ml occupied by the swelling of 1gm of 
plant material under specified conditions. A specified quantity of the plant material were 
previously reduced to the required fineness was accurately weighed and transferred into a 
25ml glass stoppered measuring cylinder. The internal diameter of the cylinder should be 
about 16mm, the length of the graduated portion about 125mm, marked in 0.2ml divisions 
from 0 to 25ml in an upward direction. Unless otherwise indicated in the test procedure, 
add 25ml of water and shake the mixture thoroughly every 10min for 1hour, allowed to 
stand for 3 hours at room temperature. The volume in ml occupied by the plant material 
was measured including any sticky mucilage. Calculate the mean value of the individual 
determination, related to 1gm of plant material. 
DETERMINATION OF VOLATILE OIL IN THE DRUG: 
 Determination of the volatile oil in a sample is done by distilling the drug with a 
mixture of water and glycerine, collecting the distillate in a graduated tube in which the 
aqueous portion is automatically separated and returned to the flask and the volume of oil 
collected is measured.  
 The content of the oil is expressed as percentage v/w. The volatile oil content was 
done by hydro distillation method by Clavenger’s apparatus 
 It is performed in the Clevenger’s apparatus.  
Procedure:  
 Weighed amount of sample is distilled with the 75 ml of glycerine and 175 ml of 
water in the one litre distilling flask with few pieces of earthen ware and one filter paper 
15 cm cut into small head. Condenser is placed above the flask and water is allowed to run 
through the condenser. Heating is discontinued after 3 to 4 hours. Volume of oil collected 
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is read in the graduated tube. The measured yield of volatile oil is taken to be the content 
of volatile oil in the drug. 
Percentage of volatile content  =  Amount of volatile oil obtained      X 100 
                   Weight of peel  
QUALITATIVE AND QUANTITATIVE ESTIMATION OF HEAVY METALS 
AND INORGANIC ELEMENTS124  
                         Plant minerals play a vital role in metabolism. Presence of elements vary 
with the soil, climate conditions etc. There are essential and non essential elements which 
may be beneficial or harmful to living things. Non essential elements like lead, arsenic, 
cyanide, chromium, cadmium, aluminium, silver bring about toxic effects resulting in 
intoxification. Hence, qualitative and quantitative estimation of inorganic elements in the 
plant Citrus maxima. (J. Burm.) Merr.  were carried out. 
QUALITATIVE ANALYSIS OF INORGANIC ELEMENTS AND HEAVY 
METALS  
                        To the ash of the drug material 50%v/v hydrochloric acid was added and 
kept for 1 hour. It was filtered and the filtrate was used for the following tests. 
Aluminium: White gelatinous precipitate of aluminium hydroxide is formed on addition 
of ammonia solution. It is slightly soluble in excess of the reagent. The precipitate 
dissolves readily in strong acid and base, but after boiling it becomes insoluble.   
Arsenic:  Arsenious salts in neutral solution react with solution of copper sulphate to form 
green precipitate (scheele’s green) which on boiling gives a red precipitate of cupric oxide. 
Borate: The mixture obtained by the addition of sulpuric acid and alcohol (95%) to a 
borate when ignited, burns with flame tinged with green. 
Calcium: Solution of calcium salts, when treated with ammonium carbonate solution, 
yield a white precipitate after boiling and cooling the mixture (it is insoluble in ammonium 
chloride solution). 
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Carbonate: Carbonate, when treated with dilute acid effervescence, liberating carbon 
dioxide which is colourless and produces a white precipitate in calcium hydroxide 
solution. 
Chlorides: Chlorides, when treated with silver nitrate solution, yield a white crude 
precipitate which is insoluble in nitric acid, but soluble after being well washed with 
water, in diluted ammonia, from which it is re precipitated by the addition of nitric acid. 
Copper: An excess of ammonia, added to a solution of a cupric salt, produces first a 
bluish precipitate and then a deep blue coloured solution. 
Iron: Solution of ferric salts, when treated with potassium ferrocyanide solution, yields an 
intense blue precipitate which is insoluble in dilute Hcl. 
Lead: Strong solution of lead salts, when treated with HCL, yield a white precipitate. 
Which is soluble in boiling water and is re deposited as crystals when the solution is 
cooled. 
Magnesium: Solution of magnesium salts, when treated with ammonium carbonate 
solution and boiled, yield a white precipitate, but yield no precipitate in the presence of 
ammonium chloride solution. 
Mercury: Solution of mercury salts, when treated with sodium hydroxide solution, yields 
a yellow precipitate. 
Nitrate: With solution of ferrous sulphate no brown colour was observed but if sulphuric 
acid is added (slow from the side of the test tube), a brown colour is produced at the 
junction of two liquids, indicating the presence of nitrates. 
Phosphate: Solution of phosphate when treated with silver nitrate with dilute ammonia 
solution and in dilute nitric acid yield yellow precipitate of normal silver ortho phosphate 
(distinction from meta and pyrophosphate) solution. 
Potassium: Moderately strong potassium salts, which have been previously ignited to 
remove ammonium salts, when treated with perchloric acid (60%) yield a white crystalline 
precipitate. 
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Silver: Solution of silver salts, when treated with potassium iodide solution yield a cream 
coloured precipitate which is insoluble in dilute ammonia solution and in nitric acid. 
Sulphates: Solution of sulphates, when treated with lead acetate solution yields a white 
precipitate which is insoluble in ammonium acetate solution and in sodium hydroxide. 
QUANTITATIVE ESTIMATION OF INORGANIC ELEMENTS125:  
Inductive coupled plasma-Optical emission spectroscopy (ICP-OES)  
         It is an excellent multi-element technique with relatively good sensitivity and 
selectivity when configured correctly. This technique utilizes the plasma as an ion source 
or light emission source are capable of producing values. 
QUANTITATIVE ANALYSIS OF HEAVY METALS 
Instrumentation parameters:  
Instrument name  : Inductive coupled plasma-Optical emission spectroscopy 
Instrument Model  : PE Optima 5300DV ICP-OES; Optical system Dual view-
axial or radial 
Detector system  : Charge coupled detector, (UV-Visible detector which is 
maintaining at -40º C) to detect the intensity of the emission line. 
Light source (Torch)  : Positioned horizontally in the sample compartment along 
the central axis of the spectrometer optics. Changing from axial to radial viewing is a 
simple software command and is accomplished by computer control of a mirror located in 
the optical path. The torch assembly of this system comprises of two concentric quartz 
tubes. 
Standard alumina injector : 2.0mm inner diameter.  
Spray chamber  : Scott type 
Nebulizer   : Cross flow gem tip. 
Preparation of sample by acid digestion method: 
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   50mg of powder was treated with acid mixture of sulphuric acid: water in the 
ratio of 4:1in the Kjeldahl flask and heated continuously till the solution is colourless. The 
sample mixture was then transferred in a 25ml volumetric flask and made up to the 
volume with distilled water. Blank solution was prepared as above without sample. 
            The standards of Arsenic, Lead, Mercury and Cadmium were prepared as per the 
protocol and the calibration curve was developed for each of them. 
Detection: 
            Samples were analyzed for the detection and quantification of the 
calcium,sulphate, borate, silver, aluminium, copper, potassium, chloride by Inductively 
Coupled Plasma Emission Spectrometry. 
7.2. PHYTOCHEMICAL STUDIES 
PRILIMNARY PHYTOCHEMICAL SCREENING 126-128 
            Phytochemical evaluation is used to determine the nature of phyto constituents 
present in the plant by using suitable chemical tests. Since the phytochemical constituents 
are responsible for the pharmacological activities of the plant. This study is essential to 
identify the constituents.  Therefore a complete investigation is required to characterize the 
Phyto constituents qualitatively and quantitatively. 
Preparation of Extracts  
            Extraction is the preliminary step involved in the phytochemical studies. It brings 
out the metabolites into the extracting solvent depends upon its polarity. 
Extraction 
             The first step was the preparation of successive solvent extracts. The dried 
coarsely powdered sample of Citrus maxima. (J. Burm.) Merr peels (500gm) was first 
extracted with n- Hexane (60-80°C) in Soxhlet apparatus and then with solvents of  
increasing polarity like ethyl acetate and ethanol at 60 - 70ºC. They were then followed 
with maceration with chloroform water. Each extract was concentrated using rotary 
vacuum evaporator. The percentage yield, colour and consistency of these extracts were 
recorded and preceded for further detailed phyto chemical and pharmacological screening. 
Materials and Method 
 
Department Of Pharmacognosy, COP, MMC, Chennai-03 Page 49 
 
PRELIMINARY PHYTOCHEMICAL SCREENING  
                 The chemical tests for various Phyto constituents in the dried powder and 
extracts of peels of Citrus maxima. (J. Burm.) Merr. were carried out as described below 
and the results were recorded. 
1. Detection of Alkaloids  
 Dragendorff’s reagent : 
             The substance was dissolved in 5ml of distilled water, to this 5ml of 2M 
HcL was added until an acid reactions occurs, then 1ml of Dragendorff’s reagent 
was added and examined for an immediate formation of an orange red precipitate. 
 Mayer’s reagent: 
           The substance was mixed with little amount of dilute hydrochloric acid and 
Mayer’s reagent and examined for the formation of white precipitate. 
 Wagner’s reagent : 
            The test solution was mixed with Wagner’s reagent and examined for the 
formation of reddish brown precipitate. 
2. Detection of Glycosides  
 Borntrager’s test : 
             The powdered material was boiled with 1ml of sulphuric acid in a test tube 
for five minutes. Filtered while hot, cooled and shaken with equal volume of 
chloroform. The lower layer of solvent was separated and shaken with half of its 
volume of dilute ammonia. A rose pink to red colour is produced in the ammonical 
layer. 
 Modified Borntrager’s test : 
            The test material was boiled with 2ml of the dilute sulphuric acid. This was 
treated with 2ml of 5% aqueous ferric chloride solution (freshly prepared) for 5 
minutes, and shaken with equal volume of chloroform. The lower layer of solvent 
was separated and shaken with half of its volume of dilute ammonia. A rose pink 
to red colour is produced in the ammonical layer.  
 3. Detection of Steroids and Triterpenoids 
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 Libermann Burchards Test: 
            The powdered drug was treated with few drops of acetic anhydride, boiled 
and cooled. Conc.sulphuric acid was added from the sides of the test tube, brown 
ring is formed at the junction of two layers and upper layer turns green which 
shows presence of steroids and formation of deep red color indicates presence of tri 
terpenoids. 
 Salkowski Test : 
          The extract was treated with few drops of concentrated sulphuric acid, red 
color at lower layer indicates presence of steroids and formation of yellow colored 
lower layer indicates presence of tri terpenoids. 
 Sulfur powder test:  
Small quantity of test solution add sulfur powder. Sulpur powder sinks at 
the bottom shows the presence of triterpenoid. 
 Nollers test: 
Test was mixed with tin and thionyl chloride. It produces pink colour which 
indicates the presence of triterpenoids. 
 
 4.  Detection of Flavonoids  
 Shinoda test : 
           To the solution of extract,  few piece of magnesium turnings and 
concentrated HCl was added drop wise, pink to crimson red, occasionally green to 
blue color appears after few minutes indicates the presence of flavonoids. 
 Alkaline reagent test : 
           To the test solution  few drops of sodium hydroxide solution was added, 
intense yellow color is formed which turns to colorless on addition of few drops of 
dilute acid indicate presence of flavonoids. 
 Zinc Hydrochloride test:  
Small quantity of extract add a mixture zinc dust and Conc HCl produces 
red colour. It indicates the presence of flavonoids.  
 5. Detection of Carbohydrates 
 Molisch’s test : 
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              To the test solution few drops of alcoholic alpha napthol and few drops of 
conc. sulphuric acid were added through the sides of test tube, purple to violet 
color ring appears at junction. 
 Fehling’s test : 
              The test solution was mixed with Fehling’s I and II and heated and 
examined for the appearance of red coloration for the presence of sugar. 
  6. Detection of Phenols  
 Ferric chloride test : 
               A small quantity of substance was dissolved with 2ml distilled water and 
a few drops of 10% aqueous ferric chloride solution was added and observed for 
appearance of blue or green color. 
  7. Detection of Proteins  
 Biuret test : 
The sample was treated with 5-8 drops of 10% w/w copper sulphate and 
sodium hydroxide solution, violet color is formed.  
8. Detection of Tannins 
 Lead acetate test : 
                The test solution was mixed with basic lead acetate solution and 
examined for formation of a white precipitate. 
 Ferric chloride test : 
                A few drops of 5% aqueous ferric chloride solution was added to 2ml of 
an aqueous extract of the drug and examined for the appearance of bluish black 
color. 
  9. Detection of Saponins  
               A drop of sodium bicarbonate solution was added to the sample and the 
mixture was shaken vigorously and left for 3 minutes. Development of any honey 
comb like froth was examined. 
   10. Detection of Gums and Mucilage 
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               Small quantities of test substances was dissolved in 5 to 10ml of acetic 
anhydride by means of heat, cooled and add 0.05ml of concentrated sulphuric acid; 
it is examined for the formation of bright purplish red color. 
    11. Detection of fixed oils and fats: 
                Small quantities of extracts were pressed between two filter papers. An 
oily stain on filter paper indicates the presence of fixed oils and fats. 
FLUORESCENCE ANALYSIS129  
                   Fluorescence analysis was carried out in day light and in UV light. The peel 
powder and extracts were treated with different solvents and the fluorescence was 
observed in day light and in near and far UV light.    
QUANTITATIVE ESTIMATION OF TOTAL PHENOLIC AND TOTAL 
FLAVONOID CONTENT130-133  
Total phenolic content (Folin – Ciocalteu’s assay) 
                 Total phenolic content of the extracts were determined using Folin –Ciocalteu’s 
assay. 0.5ml extracts were mixed with 2.5ml of 10 fold diluted Folin Ciocalteu’s reagent 
and 2.5ml of 7.5% sodium carbonate. After incubation at 40°C for 30 minutes, the 
absorbance of the reaction mixtures was measured at 765nm in a spectrophotometer. Three 
replicates were made for each test sample. Gallic acid was used as a standard and total 
phenolic content of the extract was expressed in mg of Gallic acid equivalents (mg GAE/g 
extract).  
Total Flavanoid content 
                Total flavanoid content was determined by calorimetric method, using quercetin 
as a standard. The test samples were individually dissolved in DMSO. Then the sample 
solution (150 µl) was mixed with 150 µl of 2% aluminium chloride. After 10min of 
incubation at ambient temperature, the absorbance of the supernatant was measured at 
435nm using spectrophotometer. Three replicates were made for each test sample. The 
total flavanoid content was expressed as quercetin equivalent in mg/gm extract (mg 
QRT/gm extract). 
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CHROMATOGRAPHY134-136  
               Chromatographic methods are important analytical tool in the separation,                    
identification and estimation of components present in the plant. 
THIN LAYER CHROMATOGRAPHY 
Principle 
              Thin layer chromatography is a technique used for the separation, identification 
and estimation of single or mixture of components present in the various extracts. It is 
reliable technique in which solute undergoes distribution between two phases, stationary 
and mobile phase. The separation is mainly based on the differential migration that occurs 
when a solvent flows along the thin layer of stationary phase. This may be achieved by 
partition and adsorption depending on stationary phase used. 
TLC Plate Preparation 
              The plates were prepared using Stahl TLC spreader. 40gm of silica gel G was 
mixed with 85ml of water to prepare homogenous suspension and poured in the spreader. 
0.25mm thickness of plates was prepared, air dried until the transparency of the layer 
disappeared, then dried at 110°C for 30 minutes and kept in desiccators. 
Selection of mobile phase:   
            Solvent mixture was selected on the basis of the phyto constituents present in each 
extract. Factors such as nature of components, stationary phase, mobile phase, polarity, 
influence the rate of separation of constituents. From the vast analysis, best solvent was 
selected which showed good separation with maximum number of components.   
HPTLC- FINGERPRINT PROFILE: 
           HPTLC is one of the versatile chromatographic method which helps in the 
identification of compounds and thereby authentication of purity of herbal drugs. The time 
required in this method for the demonstration of most of the characteristic constituents of a 
drug is very quick and short. In addition to qualitative detection, HPTLC also provides 
semi-quantitative information on major active constituents of a drug, thus enabling an 
assessment of drug quality.   
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           HPTLC serves as a convenient tool for finding the distribution pattern of phyto 
constituents which is unique to each plant. The fingerprint obtained is suitable for 
monitoring the identity and purity of drugs and for detecting adulteration and substitution. 
HPTLC technique is helpful in order to check the identity, purity and standardize the 
quantity of active principles present in the herbal extract. 
Instrument Conditions: 
Sample used               : Ethanol Extract 
Instrument  : CAMAG HPTLC 
HPTLC Applicator : CAMAG LINOMAT IV 
HPTLC Scanner : CAMAG TLC SCANNER II 
Sample dilution : 100mg of sample extracted with 1ml of Ethyl acetate 
Volume of injection : 20µl 
Mobile phase  : Hexane: Ethyl acetate :Chloroform: Toulene: Methanol: Formic 
 Acid (2:2:1:4:0.5: 0.5) 
Lambda max  : 254nm 
Lamp   : Deuterium 
Stationary phase       : TLC silica gel 60 F254 (Merck) 
Equipment: 
          A Camag HPTLC system equipped with a sample applicator Linomat IV, Twin 
trough plate development chamber, TLC Scanner II. 
Chromatographic conditions: 
           The estimation has been done using the following chromatographic conditions. 
Chromatography was performed on a 10 × 10cm pre-activated HPTLC silicagel 60 F254 
plate. Samples were applied to the plate as 6mm wide band with an automatic TLC 
applicator Linomat IV with nitrogen flow (CAMAG, Switzerland), 8mm from the bottom. 
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Densitometric scanning was performed on CAMAG scanner II. The plates were pre-
washed with solvent ethyl acetate. 
1.3.  SELECTION OF ACTIVE EXTRACT 
1.3.1. IN VITRO ANTI OXIDANT ACTIVITY 137-139 
There has been a lot of interest in the development of alternative medicine for memory 
impairment. Oxidative stress plays a major role in the progression of memory impairment. 
It occurs when the balances between free radicals which attack nerve cells and anti 
oxidants which protect them are lost. 
 Anti oxidants like poly phenols and flavanoids are therefore very helpful in 
maintaining the brain function and improving memory. It has become evident that 
flavanoids are able to exert neuroprotective actions even at low concentration via their 
interactions with critical neuronal intracellular signaling pathways pivotal in controlling 
neuronal survival and differentiation, long term potentiation and memory. 
 Therefore it can be concluded from various studies that anti oxidants alone can also 
be helpful in enhancement of memory. 
          In vitro antioxidant activities for the extracts were carried out using the following 
methods. 
                              1. DPPH assay 
                              2. Hydrogen peroxide scavenging assay. 
DPPH (1, 2-DIPHENYL-2-PICRYL HYDRAZYL RADICAL) ASSAY 
Initial volume 0.1 ml  of various concentrations of samples were mixed with 0.4 ml 
of 0.3M DPPH reagent prepared in ethanol. The mixture was shaken thoroughly and 
incubated in the darkness at room temperature for 30 min. The absorbance of the reaction 
was measured spectrophotometrically at 517nm, immediately after mixing and then after 
incubation as well. The scavenging effect of DPPH free radical was calculated by using 
the following equation. 
% scavenging activity = Abs (control) - Abs (standard) / Abs (control) × 100  
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Where control is the absorbance of the blank (a reaction with all the reagents except the 
test extract), and absorbance of sample is the absorbance of the test extract. Tests were 
carried out in triplicates to obtain 50% inhibition (IC50). Using Butylated hydroxy 
Toulene. 
HYDROGEN PEROXIDE SCAVENGING ASSAY (HPSA) 
                  The ability of the extracts to scavenge hydrogen peroxide was determined 
according to the method of Ruch. A solution of Hydrogen peroxide (2mmol/l\lt) was 
prepared in phosphate buffer (PH 7.4). Various concentrations of extracts (10-100µg/ml) 
were added to hydrogen peroxide solution (0.6ml).  Absorbance at 230nm was determined 
after 10min against a blank solution containing phosphate buffer without hydrogen 
peroxide. 
% scavenging activity = Abs (control) - Abs (standard) / Abs (control) × 100 
Compared with the ascorbic acid standard. 
1.3.2. IN VITRO ANTI ALZHEIMER ACTIVITY 
ANTI-ACETYLCHOLINESTERASE ASSAY140 
The enzymatic activity was determined by Ellman’s methods developed in year 1961. It is 
used to measure extract for its AChE inhibition. Electric cell was considered as the 
enzyme source, acetyl thiocholine iodide was used as substrate and 5, 5, bis 
dithionitrobenzene, a dye was used for the measurement of cholinesterase activity.   
In this assay, 150 µl of 0.1M sodium phosphate buffer (pH 8), 10 µl of test compound 
solution and 20µl of enzyme solution (0.09 units/ml) were mixed and incubated at 250C 
for 15 min. 10 µl of the DTNB solution, 10 µl of acetyl thiocholine iodide were added to 
the resultant and allowed to withstand for 10 min. The intensity of the colour produced 
were studied using spectrophotometric observation at 410 nm. Physostigmine dissolved in 
ethanol is used as a standard. Percentage of enzyme inhibition was determined using the 
formula below 
% Enzyme inhibition = [(Optical density of test-blank) X 100] 
                                      Optical density of standard-blank 
Statistical analysis: 
 All determinations were done for three times and results are reported as mean ± 
Standard deviation. IC50 values were calculated and reported. 
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7.4.. PHARMACOLOGICAL STUDIES: 
In in-vitro method, the ethanolic extract showed potent anti oxidant activity and acetyl 
cholinesterase inhibitory activity which was comparable with the standard than other 
extracts. Hence Ethanolic extract was selected for in-vivo study. 
7.4.1. ACUTE ORAL TOXICITY STUDY (FIXED DOSE PROCEDURE) OECD 
420 GUIDLINE FOR THE TESTING OF CHEMICALS141-142 
 The organization of economic co – operation and development (OECD) guideline 
425 was followed the acute oral toxic fixed dose method is a stepwise procedure with 5 
rats of single sex per step (one animal per step). Depending upon the mortality and 
morbidity status of the animal, on average of 2 to 4 steps may be necessary to allow 
judgment on the acute oral toxicity of the substance. This procedure results in the use of 
minimal number of animal  while allowing for acceptable data based scientific conclusion.  
Literature survey showed that acute toxicity of the extracts was determined according to 
the OECD guideline No. 420 (20). Male albino mice weighing 27-30 g were used for 
Methanolic Extract of Citrus maxima was given to four groups (n = 5) of animals each at 
5, 50, 300 and 2000 mg kg-1 b.w. p. o. The treated animals were under observation for 14 
days, for mortality and general behavior. No death was observed till the end of the study. 
The test sample was found to be safe up to the dose of 2000 mg/kg. So, 1/10th and 1/5th of 
the dose (200 and 400mg/kg) were selected for this study.  
7.4.2. IN VIVO EVALUATION OF ANTI ALZHEIMER ACTIVITY 
EXPERIMENTAL DESIGN:  
Materials and Methods 
Plant extract 
             Ethanolic extract of seeds of Citrus maxima., Burm.. 
Animal selection and procurement 
                 Healthy young Swiss-Albino mice (weighing about 20-30gm) were procured 
from the Madras Medical College animal house. The animals used for the entire study was 
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approved by the Institutional Animal Ethical Committee which is certified by the 
Committee for the purpose of control and supervision of experiments on animals, India. 
Approved CPCSEA Registration No: 05/243/CPCSEA           Dated: 10/08/2015. 
                   The procured animals were kept in a clean, dry polycarbonate cages and 
maintained in a well-ventilated animal house. The temperature of experimental animal 
room was maintained at 22ºC (± 3ºC) and the relative humidity was maintained from 50-
60%. Lighting was artificially maintained for 12hrs dark and 12hrs light. All the animals 
were kept in the cages for at least 5days prior to dosing for acclimatization to the 
laboratory conditions. The animals were fed with standard pellet diet and water was given 
ad libitum. Before starting the dose, the animals were fasted overnight but allowed to 
access water. 
IN VIVO EVALUATION OF ANTI ALZHEIMER ACTIVITY 
Scopalamine induced memory impairment143 
 The reversible cholinergic receptor antagonist scopolamine induces memory loss by 
impairing memory acquisition posses of short term memory in rodents and humans. 
Scopolamine also interferes in CNS cholinergic neurotransmission resulting in memory 
impairment.  
Grouping of animals 
Animals were divided into 4 groups of six animals each. 
                 Group I: Scopalamine (0.3mg/kg b.wt) was injected after training. TL(Transfer 
Laterncy) was recorded after 1 hour of injection. 
                 Group II: Rivastigmine (0.3 mg/kg b.wt) was injected for 14 days and on the 
14th day after 30min of drug administration, scopolamine (0.3mg/kg b.wt) was given i.p. 
TL was recorded after 1 hour of injection. 
                 Group III: Test drug I (200mg/kg) was given orally for 14 days and on 14th day 
after 30min of drug administration, Scopalamine (0.3mg/kg b.wt) was given i.p. TL was 
recorded after 1 hour of injection. 
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                 Group IV: Test drug II (400mg/kg b.wt) was given orally for 7 days and on 7th 
day after 90min of drug administration, Scopalamine (0.3mg/kg b.wt) was given i.p. TL 
was recorded after 1 hour of injection.   
MORRIS WATER MAZE: 
 The Morris water maze was developed by Richard Morris in 1984. It is the most 
popular task in behavioral neuroscience; and in its most basic form, it assesses spatial 
learning and memory along with nonspatial discrimination learning. Performance in the 
Morris Water Maze is acutely sensitive to manipulations of the hippocampus. 
In this model the animals are placed into a large circular pool of water and they can 
escape on to a hidden platform. The platform is hidden by its placement just below the 
water surface which is made opaque by mixing Titanium dioxide in the water. Therefore 
the platform offers no local cues to guide the escape behavior. The animal can escape from 
swimming by climbing on to the platform and with time the animal apparently learns the 
spatial location of the platform from any starting position at the circumference of the pool. 
Morris water maze consists of a large circular tank made of black opaque polyvinyl 
chloride or hardboard coated with fiber glass and resin and then surface painted white 
(1.8-2m in diameter and 0.4-0.6m high). The pool is filled upto a height of 30cm with 
water until the top of the platform is submerged 1cm below the water surface and 
maintained at around 25°C and rendered opaque by addition of small quantity of milk or 
non-toxic white color. The pool is provided with filling and draining facilities and is 
mounted at waist level. The tank is hypothetically divided into 4 equal quadrants the 
platform (11cm2 ) of 29 cm height is located in the centre of one of these 4 quadrants.  
Before beginning acquisition training, mice are given a pertaining acclimatization session 
during which they are allowed to swim in the pool for 5min without the platform. 
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Fig 18: Morris water maze 
 
The platform remains fixed in the position during the training session. Each animal 
is subjected to four consecutive trials for four days during which they are allowed to 
escape on the hidden platform and allowed to remain for 20seconds.  Mice are released 
from the four points along the perimeter of the maze arbitrarily designated as N, S, W and 
E. Escape latency time to locate the hidden platform in water maze is noted as an index of 
acquisition or learning. In case the animal is unable to locate the hidden platform within 
120seconds, it is gently guided by hand to the platform and allowed to remain there for 
20seconds.  In each training session, the escape latency was recorded. After 4 days trail 
and 14 days treatment the animals were treated with amnesia inducing agent, 30 min after 
last oral dose of test compounds. After 1 hour mice were allowed to swim and the escape 
latency were recorded.  
Y MAZE TEST:  
The Y-maze is a simple two-trial recognition test for measuring spatial recognition 
memory, it does not require learning of a rule, and thus is useful for studying memory in 
rodents, and in particular for the study of genetic influences on the response to novelty and 
recognition processes. Immediate working memory performance was assessed by 
recording spontaneous alternation behavior using Y maze made up of black painted wood. 
Each arm was 40cm long, 12cm high, 3cm wide at the bottom and 10cm wide at the top 
and converged in an equilateral triangular central area.  
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Fig 19: Y Maze. 
Each mice were placed at the end of one arm and allowed to move freely through 
the maze during an 8 minute session. The series of arm entries was recorded visually. 
Entry was considered to be complicated when the hind paws of the mouse had completely 
entered the arm. Alternation was defined as successive entries into the three different arms 
(A, B and C) on overlapping triplet sets. The percentage of triads in which all three arms 
were represented i.e, ABC, CAB or BCA but not BAB was not recorded as an alternation 
to estimate short term memory. Percentage alternation was calculated as the ratio of actual 
to possible alternation (defined as the total number of arm entries minus two), multiplied 
by hundred as shown 
 
%alternation= {(No. of alternations) / (Total arm entries -2)} x 100 
 
On the 14th day, 60 minutes after the treatment of last dose and 30 minutes after 
scopolamine dose arm entries were recorded visually and percentage alternation was 
calculated. 
ESTIMATION OF BRAIN CHOLINESTERASE (IN VIVO)144 
Acetylcholinesterase enzyme activity was estimated by Elman method. 
Reagents 
1. 0.1M phosphate buffer 
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Solution A : 5.22gm of potassium hydrogen phosphate and 4.68gm of sodium 
hydrogen phosphate are dissolved in 150ml of distilled water. 
Solution B: 6.2gm of sodium hydroxide dissolved in 150ml of distilled water. 
Solution B is added to solution A to get the deserved pH(8.0 or 7.0) and then 
finally the volume is made upto 300ml with distilled water. 
2. DTNB Reagent 
39.6mg of DTNB with 15mg of sodium bicarbonate is dissolved in 10ml of 0.1M 
phosphate buffer (pH 7.0) 
3. Acetylthiocholine (ATC) 
21.67mg of acetylthiocholine was dissolved in 1ml of distilled water. 
PREPARATION OF BRAIN HOMOGENATE 
               The animals were scarified by anaesthetized using thiopentone and  brains of the 
animals were removed quickly and placed in ice cold saline. The tissues were weighed and 
homogenized in 0.1M phosphate buffer (pH-8) and the brain homogenate was used for the 
estimation of Brain AchE level. 
 Neurotransmitter plays a main role in maintaining normal function and behaviour 
of brain. Acetylcholine is one of the most important neurotransmitter in the brain. It plays 
a large role in learning and memory. An imbalance in acetylcholine can lead to learning 
and memory problems. 
 Estimation of Brain Acetyl cholinesterase level 145-146 
                Estimation of brain AchE level provides a relatively easy and valuable 
assessment of cholinergic function. The method of AchE activity estimation is popularly 
known as Elman’s method named after George Ellman who developed this method in 
1961(Ellman et al., 1961). 
               The esterase activity was measured by providing an artificial substrate, 
acetylthiocholine (ATC). Thiocholine released because of the cleavage of ATC by AchE 
was allowed to react with the –SH reagent 5, 5’-dithiobis nitro benzoic acid, which is 
reduced to thio nitro benzoic acid, a yellow coloured anion with an absorption maxima at 
412nm. 
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ASSAY PROCEDURE 147 
9 0.4ml of aliquot of brain homogenate was added to a cuvette containing 2.6ml of 
phosphate buffer (0.1M) and to this 100µl of DTNB was added. 
9 The contents of the cuvette were mixed thoroughly by bubbling air and absorbance 
was measured at 412nm in spectrophotometer, when absorbance reaches a stable 
value, it was recorded as the basal reading. 
9 20µl of substrate (ATC) was added and change in absorbance was recorded for a 
period of 10minutess at intervals of 2minutes. Change in the absorbance per 
minute was determined. 
Reagent  Sample  Blank  
Phosphate buffer solution 2.6ml 2.7ml 
Supernatant 0.4ml 0.4ml 
DTNB 0.1ml --- 
 
                     The enzyme activity was calculated using the following formula 
  R = 5.74 (10⁻⁴) ΔA/Co,    
 R = Rate in moles substrate hydrolyzed per min per gm of tissue,    
 ∆A = Change in absorbance per min,        
 Co = Original concentration of tissue (mg/ml).  
HISTOPATHOLOGY 
The mice from each group were anaesthetized using intraperitoneal injection of 
thiopentone sodium. The brain was carefully removed without any injury after opening the 
skull. The collected brain was washed with ice cold normal saline and fixed in 10% 
formalin saline. Paraffin embedded sections were taken 100μm thickness and processed in 
alcohol-xylene series and stained with Haematoxyli-Eosin dye. The sections were 
examined microscopically for histopathological changes in the hippocampal zone. 
 
STATISTICAL ANALYSIS 
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The statistical analysis was carried by one way ANOVA followed by Dunnet’s t test. P 
values <0.05 (95% confidence limit) was considered statistically significant, using 
Software Graph pad Prism 6.0 
 
7.5. ISOLATION AND CHARACTERISATION OF PHYTOCONSTITUENTS 
BY COLUMN CHROMATOGRAPHY  
Column chromatography is an isolation technique in which phytoconstituents are 
being eluted by adsorption.  The principle involved in this separation of constituents is 
adsorption at the interface between solid-liquid. The component must have various degree 
of affinity towards adsorbent and also reversible interaction to achieve successful 
separation. No two compounds are alike in above respect. Low affinity compound will 
elute first. Adsorbent used is silica gel. 
Ethanolic extract of Citrus maxima was found to possess maximum 
phytoconstituent with potent anti Alzheimer activity. So an attempt was made to isolate 
the active constituent from the ethanolic extract by column chromatography. 
COLUMN CHROMATOGRAPHY: 
 Type of extract : Ethanolic extract 
 Method  : Dry packing method 
 Packing material : Silica gel G70-325 
A). PROCEDURE: 
The ethanolic extract was subjected to Silica gel column chromatography for 
isolation of phytoconstituents.  
An appropriate column sized 2.5 cm diameter and 60 cm length was used. It was 
washed with water and rinsed with acetone and dried completely. Little of pure cotton was 
placed at the bottom of column with help of a big glass rod. Solvent Hexane was poured in 
to the column 3/4th level. Before packing, ethanolic extract 10 gm was diluted in ethanolic 
solvent and thoroughly mixed with 30 g of graded silica gel. It was constantly mixed until 
it became free flowing. When it reached at defined state it was slowly poured in to the 
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column containing hexane solvent with slight movement of stirring by glass rod to avoid 
clogging. Once it got settled, little cotton was placed on top of silica gel extract mixture 
pack to get neat column pack. The knob at bottom was slowly opened to release the 
solvent. The elute was done using solvents of increasing polarity like hexane, followed by 
hexane-ethyl acetate mixture and ethyl acetate-ethanol mixture. Each fraction were 
collected and analyzed qualitatively. Similar fractions were mixed together, allowed to 
evaporate to remove solvent.  
B) TLC 
As soon as the fraction eluted, it was analyzed by using readymade TLC plate with 
suitable mobile solvent according to the polarity of elute.  
MOBILE PHASE 
Ethanol: Ethyl acetate  (4: 2) 
Observation 
The developed chromatogram was observed under UV, Fluorescence and also 
derivatised using detecting agent. 
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Fig 20: Method of isolation 
C). CHARACTERISATION OF ISOLATED COMPOUND 
PHYSICAL EVALUATION: 
1. Physical properties of the isolated compounds are evaluated, such as 
¾ Colour 
¾ Nature 
¾ Solubility 
¾ Molecular weight 
¾ Molecular formula 
¾ Melting point 
¾ Boiling point 
2. Further the isolated compounds were characterized by following Spectroscopic 
methods. Such as 
IR Spectroscopy 
Ethanolic extract of 
Citrus maxima 10g
Fraction 1
Very little and had 
several spots
Fraction 2
narrow band ,clear, 
single spot
Column chromatography silica
gel . Hexane, ethyl acetate,ethanol 
gradient elution
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NMR- 1H & 13C 
Mass spectroscopy 
 
IR SPECTROSCOPY148 
              Infrared (IR) spectroscopy is one of the most common spectroscopic techniques 
used by organic chemists. The main goal of IR spectroscopic analysis is to determine the 
chemical functional groups in the sample. Different functional groups absorb characteristic 
frequencies of IR radiation. IR spectroscopy is an important and popular tool for structural 
elucidation and compound identification. The possible characteristic bands of the nucleus 
are 
                     1. 3540-3300 cm-1 N-H Stretching Vibration 
                     2. 3670-3230 cm-1 O-H Stretching Vibration 
                     3. 1690-1630 cm-1 C=N Stretching Vibration 
                     4. 2975-2840 cm-1 C-H Aliphatic Stretching Vibration 
                     5. 3100-3000 cm-1 C-H Aromatic Stretching Vibration 
 
NMR SPECTROSCOPY149  
            NMR is the most powerful analytical tool currently available to an organic 
chemist. NMR allows characterization of a very small amount of sample (10mg), and does 
not destroy the sample (non-destructive technique). NMR spectra can provide vast 
information about a molecule's structure and can very often be the only way to prove what 
the compound really is. Typically though, NMR is used in conjunction with other types of 
spectroscopy and chemical analysis to fully confirm a complicated molecule's structure. It 
involves the interaction of the electromagnetic radiation and the hydrogen of the nucleus 
when placed in an external static magnetic field. Some basic characteristic peaks of the 
nucleus 
                      1. Aromatic and hetero aromatic compounds 6-8.5 δ 
                      2. Alcoholic hydroxyl protons 1-5.5 δ 
                      3. Aldehyde protons 9-10 δ 
 
MASS SPECTROSCOPY150  
             Mass Spectrometry is an analytic technique that utilizes the degree of deflection of 
charged particles by a magnetic field to find the relative masses of molecular ions and 
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fragments. It is a powerful method because it provides a great deal of information and can 
be conducted on tiny samples. Mass spectrometry has a number of applications in organic 
chemistry. They are: 
9 Determining molecular mass 
9 Finding out the structure of an unknown substance 
9 Verifying the identity and purity of a known substance 
9 Providing data on isotopic abundance. 
 
2.GC-MS: 
          It is a combined technique, used for molecular weight determination. Gas 
chromatography and mass spectroscopy combined to form GC-MS.  
 
7.5. MOLECULAR DOCKING STUDIES OF ISOLATED COMPOUND 
DOCKING STUDIES151-154 
DRUG DESIGN: 
           For the pharmaceutical industry, the number of years to bring a drug from 
discovery to market is approximately 12-14 years and costing up to $1.2 - $1.4 billion 
dollars. Traditionally, drugs were discovered by synthesizing compounds in a time-
consuming multi-step processes against a battery of in vivo biological screens and further 
investigating the promising candidates for their pharmacokinetic properties, metabolism 
and potential toxicity.  Such a development process has resulted in high attrition rates with 
failures attributed to poor pharmacokinetics (39%), lack of efficacy (30%), animal toxicity 
(11%), adverse effects in humans (10%) and various commercial and miscellaneous 
factors. Today, the process of drug discovery has been revolutionized with the advent of 
genomics, proteomics, bioinformatics and efficient technologies like, combinatorial 
chemistry, high throughput screening (HTS), virtual screening, de novo design, in vitro, in 
silico ADMET screening and structure-based drug design.  
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9 Save the download pdb (text file) to the desktop. 
Step: 2 
9 Open Argus lab file            Open            Import pdb file from the desktop. 
9 3D Structure of the protein will appear in the workspace of Argus lab. 
9 Left side of the screen shows molecular tree view. 
9 Open pdb           Open ‘residues’           ‘Open misc’ 
9 From ‘Misc’ delete the inhibitor and hetero residues [Note: Do not delete Co-
factor] 
9 Open water press shift, select all water molecules and delete. 
9 Add hydrogen atoms. 
9 Go to Calculation on the toolbar           energy by UFF method         start. 
9 Save the prepared protein as *.agi file format in the desktop. 
2. Q-SITE FINDER 
Step: 1 
9 Open Q-Site finder through online. 
9 Upload / Import the PDB format of the Protein. 
9 Find all the active site and make a list out of the common amino acid residues. 
Step: 2 
9 Open residues          open Amino acids. 
9 Press control and select the amino acid which was listed from the Q-Site finder. 
9 Make sure that all amino acid residues listed are selected. 
9 Right click on the mouse        make a group from the selected residues      give 
name         Binding site           Ok. 
 
3. LIGAND PREPARATION 
9 Draw the structure from Chem sketch and save as MDL Mol format. 
9 Import the ligand into workspace of Argus lab. 
9 Clean Geometry          Clean Hybridisation. 
9 Select the ligand, Right click on the mouse        Make a group from the residues         
give name        ligand         Ok. 
 
4. DOCKING PROCEDURE 
9 Select the set up a Dock Ligand calculation from the toolbar. 
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9 Argus Dock as the Docking Engine. 
9 Dock was selected as calculation type. 
9 Flexible for the scoring function. 
9 Calculation size. 
9 Start docking. 
9 Save the Docked protein Ligand complex as Brookhaven pdb files (*.pdb) 
5. VISUALIZATION / INTERPRETATION OF DOCKING 
      Molegro Molecular viewer will help in analyzing the energies and interaction of the 
binding. 
9 View          Secondary Structure view. 
9 View          Hydrogen bond interaction. 
9 Ligand map          Interaction overlay. 
PREPARATION OF ENZYMES TO ANALYSE ANTI ALZHEIMER ACTIVITY 
The target for docking studies was selected as Acetyl cholinesterase, Human Butyl 
cholinesterase and Beta secretase. 
Docking analysis is done by selecting the target for disease and followed by 
obtaining the 3D structure of Human Acetyl Cholinesterase (PDB ID: 1B41), Beta 
secretase (BACE-1 PDB ID: 1W51), Human Butyryl cholinesterase (PDB ID: 1POP) from 
protein data bank in .pdb format.  
MOLEGRO VIRTUAL VIEWER:  
This soft ware was used in order to find the hydrogen bonds, Electrostatic 
interactions, Steric interaction and Ligand to receptor binding were observed after the 
results of docking being saved in the .agi format. 
LIGANDS TO BE DOCKED 
COMPOUND 1 
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RIVASTIGMINE 
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8. RESULTS AND DISCUSSION 
8.1.  PHARMACOGNOSTICAL STUDIES: 
Pharmacognostical studies play a key factor in establishing the authenticity of the 
plant material. The botanical identity of the seed was established by examining its 
anatomical features. 
Citrus maxima (J. Burm.) Merr of Rutaceae is widely distributed and indigenous in 
Indian subcontinent. Citrus maxima is a perennial shrub commonly known as Papanus. 
The peel of the fruit has leathery endocarp, containing numerous oil glands.  The results of 
the pharmacognostical studies are as follows. 
Organoleptic characters 
Nature  - Coarse powder 
Colour  - Pale yellow 
Odour   - Aromatic 
Taste  - Bitter 
Morphological Features: 
Mature fruits are  
Table No: 2: Morphological features of fruits 
Sno Parameters Observation 
1 Size 7.9 cm in diameter  
2 Shape   spherical in shape, Globose 
or pyriform  
3 Colour Green to greenish yellow 
4 Odour Aromatic  
5 Taste Sour and bitter.  
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PEEL  
Table No 3: Morphological features of Peels 
S.no  Parameters  Observation in fresh peel  Observation  in Dried peel  
1  
Colour  
Outer surface  
Inner surface  
 
Yellowish green  
White               
                            
Yellowish brown  
Brown  
2  Taste  Sour  and Bitter  Sour  and Bitter  
3  Odour  Aromatic  Less aromatic  
4  Surface  Spongy and  pitted  Hard and pitted  
5  Thickness  2-2.5 cm  0.5- 1 cm  
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Fig 22: Measurement of citrus fruit 
        
                  Fig 23: Fresh peel    Fig 24:Dried peels 
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Fig 25: Pulps of fruit     Fig 26: Seeds of Citrus maxima 
MICROSCOPY:  
Fruit ranges from nearly round to oblate or pear-shaped; 10-30 cm wide, the peel, 
clinging or more or less easily removed, may be greenish-yellow or pale-yellow, minutely 
hairy, dotted with tiny green glands; 1.25-2 cm thick, the albedo soft, white or pink. 
Microscopy of Citrus maxima peel:   
Peels are leathery and thick in nature. The transverse section of the peel showed 
the presence of the epidermal cell, parenchymal cells, Collenchymatous cell and vascular 
bundle.  
Epidermal cells:  
 They are present at the outer layer of the peel. They are arranged without any 
intracellular spaces.Fig:27 
Parenchymatous cell:  
Arranged horizontally along with the epidermal cells, oil glands and oil globules 
are arranged in these parenchymatous layer. Fig: 29 
Vascular bundle:  
Xylem and Phloem are found in the peel as meta xylem are found at the periphery. 
Fig: 30 
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Collenchymatous cells:  
These are present in the middle layer of the peels without any intracellular spaces. 
Fbres are present in these layers. Fig: 12 
Crystal sheath and calcium oxalate are present in the parenchymatous layer of the 
peel.  
   
Figure 27: TS of Citrus maxima peel  10 X  Figure 28: TS of Citrus maxima peel  20X 
EP- epidermis, VS- vessels, OG- oil globules 
       
Fig 29: TS of Citrus maxima peel 40X Fig 30: TS of C.maxima peel showing vascular  
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       bundle 
XY- Xylem, PH- Phloem, CL- Collenchymatous cell, PC- parenchymatous cells, XY- 
Xylem. 
   
Fig 31: TS of Citrus maxima peel  100X Figure 32: TS of Citrus maxima peel  100X 
CAO- calcium oxalate crystals.  CL- Collenchymatous cell. 
      
Fig 33: TS of Citrus maxima peel  100X    Fig 34: TS of Citrus maxima peel  100X 
SC- stone cells, SC- Sclerenchymatous cell, OG- Oil globules. 
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Fig 35: TS of Citrus maxima peel 100X.       Fig 36: TS of citrus peel 100x  
FB- Fibres vessels and CS- crystal sheath 
POWDER MICROSCOPY: 
Powder microscopy of the peels of Citrus maxima was observed and it showed the 
presence of fibres, xylem vessels, stone cells and calcium oxalate, oil cells were also 
observed. 
These features can be employed for inter specific identity of drugs.  
        
Fig 37: Oil Globules    Fig 38: Fibres 
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Fig 39: Cluster of stone cell   Fig 40: Calcium oxalate crystal 
                 
 Figure 41: vessels 
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HISTOCHEMICAL COLOUR REACTIONS: 
                Histochemical analysis is done in order to detect presence of phytoconstituent 
and their nature. The Histochemical analysis showed the presence of Lignin, Starch and 
Tannin in xylem, Middle layer near oil globule and vascular bundle. Reports are described 
in Table 4, Fig 42. 
 
Table No 4:  Histochemical colour reactions of Citrus maxima. 
 
Sno Chemicals Test for Nature of 
change 
Histology Degree of 
change 
1 Phloroglucinol + HCl 
 
Lignin Pink xylem + 
2 N / 50 Iodine Solution Starch Blue Middle layer 
near oil 
globules 
+ 
3 Dil. Ferric Chloride Tannin Black Vascular 
bundles 
+ 
4   Picric acid  Protein  No yellow 
colour 
-- - 
5 Dragendroff’s reagent  Alkaloid No orange 
colour  
-- - 
Note: + -- Indicates the prescence, - indicates absence 
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       Black colour                   Pink coloured   Blue coloured 
         Tannins Lignin   Starch 
Fig 42: Histochemical analysis of the peels of Citrus maxima. 
PHYSIO-CHEMICAL CONSTANTS 
Physiochemical parameters are mainly used in judging the purity and quality of the 
powdered drug. Ash values of a drug give an idea of the earthy matter or inorganic 
elements and other impurities present along with the drug. 
              Ash values are mainly used in judging the purity and quality of the drug is the 
indicative of contamination, substitution and adulteration. The total ash usually consists of 
carbonate, phosphate and silicates. Total ash, acid insoluble ash and water soluble ash 
were done and reported in the table below (Table No 5). 
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Table No  5: The Physiochemical analysis of the peels of Citrus maxima .  
S.NO PHYSIO-CHEMICAL CONSTANTS RESULTS (%w/w) 
I ASH VALUES 
1. Total ash 3.26 ± 0.15 
2. Water soluble ash 0.72± 0.06  
3. Acid insoluble ash 0.89 ± 0.15 
4. Sulphated ash 1.00 ± 0.15 
II EXTRACTIVE VALUE 
1. Water soluble extractive 28.34 ± 1.44 
2. Alcohol soluble extractive 10.56 ± 0.19   
3. Ether soluble extractive 2.22 ± 0.12 
4 Non volatile ether soluble extractive 2.08±  0.14 
III Loss on drying 5.69 ± 0.19% 
IV Swelling index 1.5 ml 
V Foaming index NIL 
VI Volatile oil content 6% V/W 
Values are expressed as Mean ± SD, n=3 
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INORGANIC ELEMENTS AND HEAVY METAL ANALYSIS 
       Qualitative and quantitative estimation of inorganic metals were analyzed using 
Inductive coupled plasma analysis method and the results were tabulated as follows. 
      Table No 6. Qualitative estimation of inorganic elements of Citrus maxima. 
S.No INORGANIC ELEMENTS OBSERVATIONS 
1. Aluminium + 
2. Chloride + 
3. Copper - 
4. Calcium + 
5. Iron - 
6. Borate + 
7. Potassium + 
8. Carbonate - 
9. Sulphates - 
10 Silver - 
11 Nitrate + 
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Table No 7: Quantitative estimation of inorganic elements of Citrus maxima. 
S.NO   INORGANIC ELEMENTS  
TOTAL AMOUNT    
(% W/W) 
1.  Aluminium  0.018  
2.  Chloride  0.044  
3 Calcium  0.032  
4.  Borate  0.004  
5.  Potassium  0.049  
6.  Nitrate  0.011  
 
Quantitative estimation of Heavy metals by ICP OES method 
           The quantification of the individual heavy metals was analyzed for the powdered 
mixture of Citrus maxima by ICP-OES technique the following metals  like arsenic, lead, 
cadmium were detected and quantified, results are given in the following table 
Table No 8: Quantitative estimation of Heavy metals 
S.NO ELEMENT  RESULTS (PPM) SPECIFICATION 
AS PER WHO GUIELINES 
1. Mercury      Not detected Not more than 0.5ppm 
 
2. Arsenic        0.023 Not more than 5.0ppm 
 
3. Lead        0.032 Not more than 10ppm 
 
4. Cadmium        0.001 Not more than 0.3ppm 
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The above  observation showed that the heavy metals are within the limits as per 
WHO standard and it is safe to consume internally. 
8.2.  PHYTOCHEMICAL STUDIES 
EXTRACTION: 
Extraction with the various solvent were performed, percentage yield and 
phytochemical analysis were done. The percentage yield of each extract are tabulated 
below. 
Table No 9: Percentage yield of successive extracts of peels of Citrus maxima. 
S.NO EXTRACT METHOD  
OF EXTRACTION
 
 
PHYSICAL 
NATURE 
COLOUR YIELD 
(%W/W) 
 
1. Hexane 
 
 
 
 
 
 
 
Continuous Hot 
percolation method 
using Soxhlet 
apparatus 
Oily liquid Yellowish 
brown 
1.2 
2. Ethyl acetate 
 
 
 
Semisolid Brown in 
colour 
2.3  
3. Ethanol 
 
 
 
Semisolid Dark brown in 
colour 
8.8 
4 Water Cold Maceration  Semi solid and 
sticky 
Dark brown in 
colour 
7.5 
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PHYTOCHEMICAL ANALYSIS 
         The phytochemical analysis of various extracts were performed and presence of 
flavonoid, tannins, saponins and steroids were significant. 
Table No 10: Qualitative Phytochemical analysis  
SNO TESTS POWDER HEXANE
ETHYL 
ACETATE
ETHANOL AQUEOUS
1 Alkaloids - - - - - 
2 Flavonoids + + + ++ + 
3 Phytosterols + - - + - 
4 Triterpenoid + - + + + 
5 
Tannins and 
phenolic 
compound 
+ 
- + + + 
6 Saponins + - - + + 
7 
Gums and 
mucilage 
+ 
- - + + 
8 Carbohydrates + - - + + 
9 Glycosides - - - - - 
10 
Proteins & 
amino acids 
- 
- - - - 
11 Steroids + - + + + 
12 
Fixed oils and 
Fats 
- 
- - - - 
Note: + indicates presence, - indicates absence 
QUANTITATIVE ESTIMATION OF PHYTOCONSTITUENTS 
The Citrus maxima Burm., was found to contain various phytochemical 
constituents and hence it is desirable to quantify few of them in order to establish a 
standard to maintain its quality. Among them the estimation of total Flavonoids and 
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phenolic content in the ethanol and ethyl acetate extract were decided to be taken as 
parameters.  
TOTAL FLAVONOID CONTENT 
           Total flavonoid content was determined and compared with that of standard and 
thus ethanolic extract was found to have higher absorbance than ethyl acetate. It is 
represented in Table No 11. 
Table No 11:  Determination of Total Flavanoid content  
  S.No Concentration of standard 
Quercetin solution(µg/ml) 
Absorbance(765nm) 
1. 2 0.07 
2. 4 0.10 
3. 6 0.13 
4. 8 0.16 
5. 10 0.20 
6. Ethyl Acetate 0.12 
7. Ethanol 0.17 
 
Standard calibration curve for determination of Total Flavonoid Content 
 
Fig 43: Total Flavonoid content 
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TOTAL PHENOLIC CONTENT 
             Total phenolic content was determined and compared with that of standard and 
thus ethanolic extract was found to have higher absorbance than ethyl acetate. It is shown 
in Table No 12. 
Table 12: Determination of Total Phenolic Content  
S.No Concentration of standard 
Gallic acid solution(µg/ml) 
Absorbance 
(765 nm) 
1. 20 0.13 
2. 40 0.16 
3. 60 0.19 
4. 80 0.22 
5. 100 0.25 
6. Ethyl Acetate 0.15 
7. Ethanol 0.17 
 
Calibration curve for determination of total Phenolic content 
 
Fig 44: Total Phenolic Content  
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The Flavonoid and phenolic content present in the extract were determined 
quantitatively. 
Total Phenolic and Flavonoid content of extracts of Citrus maxima  are represented 
in table no 13. 
Table N0 13: Quantitative estimation of phytoconstituents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No EXTRACT TOTAL FLAVANOID  
CONTENT 
TOTAL PHENOLIC 
CONTENT 
1. Ethyl acetate 5.250µg/mg                       
 
50.25 µg/mg 
2. Ethanol  8.375µg/mg                       
 
70.42 µg/mg 
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FLUORESCENCE ANALYSIS 
Fluorescent analysis of powder and extracts were analysed in day light and under 
UV of 265 nm and 365 nm.  
 
Table No 14: Fluorescence characteristic of powdered samples of Citrus maxima at short 
UV and long UV. 
TREATMENT  DAY LIGHT  
SHORT UV (254 
nm)  
LONG UV (365 
nm)  
Drug  Pale white  Dark brown  Orange  
Drug + Water  Light yellow  Light yellow  Orange  
Drug + 1 N Hcl  Light yellow  Dark green  Pale yellow  
Drug + 1 N HNO3  Light yellow  Dark green  Brownish yellow  
Drug + 1 N H2SO4  Reddish brown  Blackish brown  Dark brown  
Drug + Acetic acid  Light yellow  Pale green  Yellowish brown  
Drug + 1N NaOH  Dark yellow  Greenish brown  Orange  
Drug + 1N Alc 
NaOH  
Dark yellow  Greenish brown  Orange  
Drug + 1 N KOH  Dark yellow  Greenish brown  Pale brown  
Drug + 1N Alc 
KOH  
Dark yellow  Greenish brown  Pale brown  
Drug + Ammonia  Dark yellow  Dark green  Dark orange  
Drug + Iodine  Brownish orange  Brownish green  Reddish green  
Drug + Fecl3  Brownish green  Brownish green  Dark green  
Drug + Picric acid  Dark yellow  Dark green  Brownish green  
Florescence characteristics of the extracts  of the peel of Citrus maxima. 
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Table No 15: Fluorescence characteristic of extracts of Citrus maxima at short UV 
and long UV. 
EXTRACT DAY LIGHT 
SHORT UV (254 
nm) 
LONG UV (365 
nm) 
Hexane  Pale brown Reddish brown Brown  
Ethyl acetate Pale brown Brownish red Brown 
Ethanol Brown Reddish brown Brown 
Aqueous  Brownish black Blackish green Dark Brown 
 
TLC OF EXTRACTS:  
Thin Layer Chromatogrphy of the various extracts were performed and Rf value 
was determined.  
Table No 16. Thin layer chromatography of Various extract. 
SNO EXTRACTS SOLVENT SYSTEMS NO OF 
SPOTS 
Rf value  
1 Hexane  Ethyl acetate: Ethanol: Water 
(100: 13.5: 10) 
1 0.93 
2 Ethanol Ethyl acetate: Ethanol: Water 
(100: 13.5: 10) 
4 0.33 
0.52 
0.74 
0.89 
3 
 
Ethyl acetate Ethyl acetate: Ethanol: Water 
(100: 13.5: 10) 
3 0.33 
0.73 
4 Water Ethyl acetate: Ethanol: Water 
(100: 13.5: 10) 
2 0.22 
0.74 
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Table No 17: Solvent system of HPTLC analysis 
EXTRACT SOLVENT 
Ethanolic extract Hexane : Ethyl acetate : Chloroform : 
Toulene : Methanol : Formic acid   
(2: 2 : 1: 4: 0.5: 0.5) 
Derivatizing agent: 10% Anisaldehyde 
sulphuric acid 
Lamp: Tungsten 
 
 
 
 
Fig 46: HPTLC Chromatogram 
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Histogram for Citrus maxima HPTLC data 
 
 
 
Fig 47: HPTLC finger print for  Citrus maxima 
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Table No 18: HPTLC profile of extracts 
 S.No Rf Height Area Lamda Max 
1 0.10 19.6 342.8 737 
2 0.11 15.2 131.4 800 
3 0.17 2.4 28.6 507 
4 0.19 3.6 88.3 507 
5 0.25 9.7 156.7 507 
6 0.27 9.0 153.5 507 
7 0.33 0.9 25.0 507 
8 0.44 1.5 34.5 507 
9 0.52 7.8 382.1 507 
10 0.74 3.3 124.7 507 
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8.3.SELECTION OF ACTIVE EXTRACT 
 
8.3.1. ANTIOXIDANT ACTIVITIES 
A number of studies shown that oxidative stress is involved in age related 
neurodegenerative diseases. Likewise, there are numerous studies which have examined 
the positive benefits of antioxidants to reduce or block neuronal death occurring in the 
pathophysiology of these disorder. In addition, the antioxidant potential of a compound 
can be attributed to its radical scavenging ability and total antioxidant activity. In order to 
determine the ability of the plant extracts to serve as antioxidants, two activities were 
measured; ability to scavenge DPPH and Hydrogen Peroxide Scavenging assay. 
 
DPPH radical scavenging activity : 
Various extracts were studied for its anti oxidant activity using 1, 2-diphenyl-2-
picryl hydrazyl radical (DPPH). Results are discussed in Table 1 & Fig 1 
 
Table 19: DPPH Radical Scavenging activity of various extract  
 
S.N
O 
CONCENTRATI
ON 
(µG/ML) 
% INHIBITION 
STANDA
RD   
 (BHT) 
HEXAN
E 
ETHYL 
ACETA
TE 
ETHAN
OL 
AQUEO
US 
1. 20 53.95 19.43 23.61 45.94 19.34 
2. 40 64.81 29.32 31.28 59.86 29.34 
3. 60 76.62 30.54 33.59 68.18 30.34 
4. 80 85.21 31.34 43.16 76.95 34.32 
5 100 91.45 37.34 52.23 88.87 37.45 
IC50 (µg/ml) 10 152 97 25 147 
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Fig 1: DPPH Radical Scavenging activity of various extract 
 
 
The DPPH is a stable free radical which produced deep purple colour by accepting 
the proton from any proton donor substance and widely used to test free radical 
scavenging effect. The reduction of DPPH decreases its absorbance at 517 nm due to 
colour change. The ethanolic extract of Citrus maxima peel showed IC50 value (µg/ml) of 
25 where as Hexane, Ethyl acetate and aqueous extract showed Ic50 (µg/ml) value 152, 97, 
147 respectively. Whereas the IC50 (µg/ml) value of standard BHT was 10. Ethanolic 
extracts of Citrus maxima peel are found to produce good scavenging activity in 
comparison to other extracts. 
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HYDROGEN PEROXIDE RADICAL SCAVENGING ACTIVITY: 
  
 The Hexane, ethyl acetate, ethanol and aqueous extracts were subjected to 
hydrogen peroxide radical scavenging assay and the results are tabulated below in Table 2 
& Fig 2. 
 
Table No 20: Hydrogen peroxide Radical Scavenging activity of various extract 
 
SN
O 
CONCENTRATI
ON 
% INHIBITION 
STANDAR
D 
(ASCORB
IC ACID) 
HEXAN
E 
ETHYL 
ACETAT
E 
ETHANO
L 
AQUEO
US 
1 20 µg/ml 32.23 16.43 36.51 40.43 12.34 
2 40 µg/ml 38.13 20.32 42.23 45.65 24.54 
3 60 µg/ml 56.34 23.34 46.43 50.81 28.45 
4 80 µg/ml 73.32 29.34 52.34 57.65 32.54 
5 100 µg/ml 88.34 43.23 53.43 65.56 38.56 
IC 50 (µg/ml) 47 127 77 54 131 
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Fig 49 : Hydrogen peroxide Radical Scavenging activity of various extract 
 
 
 
The ability of the extract to scavenge hydrogen peroxide was determined in this 
method. Absorbance is measured at 230 nm and IC50 (µg/ml) value has been calculated 
and was found to be 54 for Ethanol, Were as Hexane, Ethyl acetate and Aqueous extract 
showed the IC50 –value (µg/ml) of 127,77 and 131 respectively. IC50 value of standard 
Ascorbic acid was 47. 
Ethanolic extract of Citrus maxima peel was found to produce good scavenging 
activity which is comparable with that of the standard. 
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8.3.2. ANTI-ACETYLCHOLINESTERASE ASSAY 
 In vitro assay were performed on various extracts to select the extract for the 
further studies. In this assay the percentage inhibition were noticed for all the extracts. The 
extract with least IC50 value shows good inhibition. The results are tabulated below in 
Table no: 21 
Table 21: Acetyl cholinesterase assay of various extract 
EXTRACT  IC50  VALUE  
Hexane extract  215 µg/ml  
Ethyl acetate extract  159 µg/ml 
Ethanol extract  115 µg/ml 
Aqueous extract  950µg/ml 
 
Fig 50: Acetyl cholinesterase assay of various extract 
 
The acetyl cholinesterase enzyme is a biomarker in amnesia. In this assay the percentage 
enzyme inhibition has been recorded for all the extracts. The ethanolic extract showed IC50 
value of 115 µg/ml were the hexane, ethyl acetate, aqueous extract shown the IC50(µg/ml) 
value of 215, 159 and 950 respectively. It was observed that all the extract posses 
inhibitory activity against AChE, but ethanolic extract of Citrus maxima had good AChE 
inhibitory activity. Ethanol used as a solvent and it produced better activity as compared to 
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aqueous is described in various reports25. The higher activity of the ethanolic extract may 
be due the organic solvents which are able to extract compounds with higher AChE 
inhibitory activity26. Thus the ethanolic extract can be used for the further studies. 
The ethanolic extract of Citrus maxima peel shown good enzyme inhibition 
activity. Hence they were subjected to in vivo Pharmacological studies and result are 
tabulated in Table 21 and plotted in Fig 50. 
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8.4.PHARMACOLOGICAL STUDIES 
8.4.1. IN VIVO ANTI ALZHEIMER ACTIVITY: 
The Ethanolic extract of Citrus maxima (EECM) were selected based on the above 
in vitro studies. It was given on the Mice in the dose of 200 and 400 mg selected as 1/10 
and 1/5 th of the dose which was proved to be non toxic in acute toxicity studies.  
Mice were studied for transfer latency using Morris Water Maze and Y maze. The 
transfer latency are tabulated in table 22 & 23 and plotted in Fig 51& 52. 
Table No 22: Effect of transfer latency using Morris Water Maze 
SNO  GROUP  TREATMENT  ACQUISITION 
MEMORY  
(Sec) 
RETENTION 
MEMORY 
Day 15 (Sec) 
1  I  Negative control  
Scopalamine (0.3 
mg/kg) 
19.66 ± 1.632b  18.88±1.602 a
2  II  EECM 200 mg/kg 18.66 ± 1.96a  15.5 ± 1.51b  
3  III  EECM 400 mg/kg  14.16 ± 1.60a  10.66 ± 0.80a  
4  IV  Rivastigmine  
(0.3 mg/kg) 
14.5 ± 1.37a  10.16 ± 1.47a  
 
Mean ±SD, n=6. 
All values are expressed as Mean ±SD and datas were analysed by One Way 
Annova followed by Dunnett’s test a-P<0.05: b-P<0.01 when compared with control 
group 
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Fig 51: Morris water Maze Method. 
 
Y MAZE 
 
Table No 23: Effect on Transfer Latency using Y  Maze 
GROUP  TREATMENT  %  ALTERATION OF 
MICE 
I  Negative control  
Scopalamine (0.3 mg/kg) 
26.125± 0.63*  
II  EECM 200 mg/kg  35.23 ± 0.75%**  
III  EECM 400 mg/kg  38.54 ± 0.56%**  
IV  Rivastigmine (0.3 mg/kg)  45.26 ± 0.43% * 
Mean ±SD, n=6 
%alternation= {(No. of alternations)x 100   
      (Total arm entries -2)}  
All values are expressed as Mean ±SD and datas were analysed by One Way 
Annova followed by Dunnett’s test P*<0.05: P**<0.01 when compared with control group 
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Fig 52: Effect on Transfer Latency using Y Maze 
 
Study was done on Day 14 after the last dose of daily dose. Number of alterations 
and total arm entries were measured and Percentage alteration were calculated. 
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8.4.2. ESTIMATION OF BRAIN ACETYL CHOLINESTERASE ACTIVITY: 
Brain is homogenized after the treatment and measured for the acetyl 
cholinesterase level using Elman’s method.  
Table No 24: Brain Acetyl cholinesterase level 
 
GROUP TREATMENT  AChE Level 
Mmoles/Mg Protein 
I Negative control  
Scopalamine (0.3 mg/kg) 
32.00±0.522a 
II EECM 200 mg/kg  19.00±0732a 
III EECM 400 mg/kg  22.00±0.593b 
IV Rivastigmine (0.3 mg/kg)  27.00±1.06b 
Mean ±SD, n=6. 
All values are expressed as Mean ±SD and datas were analysed by One Way Annova 
followed by Dunnett’s test a-P<0.05: b-P<0.01 when compared with control group 
 
 
Fig 53: Brain acetyl cholinesterase level 
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8.4.2. HISTOPATHOLOGY: 
Histopathology of the brain of various rats were analyzed and figured out. 
 
    
Figure 54: Histopathology of Group I   Figure 55: Histopathology of Group II  
(SCOPALAMINE INDUCED)   (200mg/kg) 
Slight increase in density of the neuronal cells   Significantly decrease in density of the  
neuronal cells 
      
Figure 56: Histopathology of Group III Figure 57: Histopathology of Group IV  
(400mg/kg)    (Standard) 
Significantly increase in density of the   Normal density of neuronal cells. 
neuronal cell  
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8.5. ISOLATION OF COMPOUND BY COLUMN CHROMATOGRAPHY: 
 
A). COLUMN CHROMATOGRAPHY 
  
The eluates obtained from silica gel column chromatography of ethanolic extract with 
different fraction are tabulated in table no 25 
Fractionation of Ethanolic extract 
Table No 25: Fractionation of Ethanolic extract 
ELUENT SOLVENT RATIO FRACTION 
n-Hexane  100% 0 
Ethyl acetate: 
Hexane 
10:90 1-3 
Ethyl acetate: 
Hexane 
20:80 4-6 
Ethyl acetate: 
Hexane 
30:70 7-11 
Ethyl acetate: 
Hexane 
40:60 12-16 
Ethyl acetate: 
Hexane 
50:50 17-21 
Ethyl acetate: 
Hexane 
60:40 22-26 
Ethyl acetate: 
Hexane 
70:30 27-31 
Ethyl acetate: 
Hexane 
80:20 32-36 
Ethyl acetate: 
Hexane 
90:10 37-41 
Ethyl acetate 100% 42-46 
Ethyl acetate: 90:10 47-50 
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Ethanol 
Ethyl acetate: 
Ethanol 
80:20 51-54 
Ethyl acetate: 
Ethanol 
70:30 55-58 
Ethyl acetate: 
Ethanol 
60:40 59-62 
Ethyl acetate: 
Ethanol 
50:50 63-66 
Ethyl acetate: 
Ethanol 
40:60 67-70 
Ethyl acetate: 
Ethanol 
30:70 71-74 
Ethyl acetate: 
Ethanol 
20:80 75-78 
Ethyl acetate: 
Ethanol 
10:90 79-82 
Ethanol 100% 83-86 
 
 
Thin layer chromatography of isolated fractions  
Solvent system:  
Ethanol: Ethyl acetate: glacial acetic acid: water (4:1: 0.5: 0.5) 
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Table No 26 : Thin layer chromatography of isolated fractions 
SNO FRACTION COMPOUND Rf VALUE 
1 0 - - 
2 1-3 - - 
3 4-6 - - 
4 7-11 - - 
5 12-16 - - 
6 17-21 - - 
7 22-26 - - 
8 27-31 - - 
9 32-36 - - 
10 37-41 - - 
11 42-46 - - 
12 47-50 C1 0.8 
13 51-54 C1 0.8 
14 55-58 C1 0.8 
15 59-62 C1 0.8 
16 63-66 C1 0.8 
17 67-70 C2 0.85 
0.89 
18 71-74 C2& 3 0.85 
0.89 
19 75-78 C2&3 0.85 
0.89 
20 79-82 C2&3 0.85 
0.89 
21 83-86 C2&3 0.85 
0.89 
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Characterization of isolated compound 
Physical properties of the isolated compounds are evaluated, such as 
¾ Colour   :Yellowish brown  
¾ Nature   : Semisolid 
¾ Solubility   : Soluble in Ethanol and water 
¾ Molecular weight  : 298.29006  
¾ Molecular formula  : C17H14O5 
¾ Boiling point  :85-870C 
Spectral analysis: 
The compound Compound 1 obtained from ethanolic extract have identified and spectral 
datas were depicted in the figure below.  
Compound 1 
IRυcm-1: Nujol mull  
Table No 27: IR Interpretation 
WAVE NUMBER INTENSITY TYPE 
3390 Broad O-H stretching 
2926 Sharp Benzene 
2090 Weak band C-H stretching in CH2 and 
CH3 
2856 Sharp  C-H Stretching in CH3 
1900-1600 Moderate >C= O Carbonyl group 
1650-1450 Sharp Aromatic C=C stretching  
1451 Sharp  C-H stretching 
1382 Sharp C-H def Methyl 
1272  Moderate Phenol 
1077 Moderate  C-O-C stretching 
775 Sharp Ortho substituted benzene 
970-700 Sharp -CH=CH2 
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GC-MS 
GC MS m/z 298 [M+], 269 [M+ - OH]; 212 [M+ -OCH3]; thus called as C17H14O5 
NMR  
1H- NMR (CDCl3, 500 MHZ) δ 5.34-5.38 (2 H, Multiplet, H-2), 4.20-4.23 ( 2H,Multiplet, 
H-5), (4 H, multiplet,substituted phenyl), 1.60-1.76(5 H, Multiplet, Benzopyran), 1.39 (1 
H, singlet, H-3) 2.00-2.10. 
13C NMR (CDCl3 ,125 MHz) δ- 68.17, 62.12, 45.63, 38.72, 33.71, 31.95, 31.35, 30.36, 
29.7, 28.93, 27.32, 24.87-24.71, 23.74, 22.99, 18.41, 14.06-14.13, 10.97 
The result finalized that Compound I was denoted as C-I and IUPAC Name was 5-
hydroxy-7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one. 
 
 
 
Fig 58: Spectrum of compound1. 
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Structure of the compound was found to be  
 
 
O
O
O
OH
CH3
O
CH3
 
 
5-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.6.IN SILICO DOCKING RESULTS 
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DOCKING SCORE AND VIEW 
HUMAN CHOLINESTERASE ENZYME (PDB ID: 1B41) 
Table No 28a: Docking against Human cholinesterase enzyme 
Compound  Structure Docking 
score 
Kcal/mol 
Docking view 
Compound 1 s -9.321  
 
 
Rivastigmine  
 
 
 
ON
O
CH3
CH3
N
CH
CH3
CH3
 
-9.816  
 
 
 
DOCKED WITH ACETYL CHOLINESTERASE 
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Fig 59a: Amino acid interaction with Acetyl cholinesterase 
COMPOUND-1 STANDARD 
 
HYDROGEN INTERACTION 
Fig 59b: Hydrogen  interaction with Acetyl cholinesterase 
COMPOUND-1  RIVSTIGMINE 
 
          
DOCKED WITH  HUMAN BUTYRYL CHOLINESTERASE (PDB ID: 1POP) 
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Table No 28b: Docking against Human butyryl cholinesterase enzyme 
COMPOUN
D  
STRUCTURE DOCKI
NG 
SCORE 
KCAL/
MOL 
DOCKING VIEW 
Compound 
1 O
O
O
OH
CH3
O
CH3
 
-7.759  
    
 
Rivastigmin
e 
 
 
 
ON
O
CH3
CH3
N
CH3
CH3
CH3  
 
-7.803  
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Fig 59c: Amino acid interaction with Human butyryl cholinesterase enzyme 
COUMPOUND 1  Rivastigmine  
       
HYDROGEN INTERACTION 
Fig 59 d: Hydrogen interaction with Human butyryl cholinesterase enzyme 
                      COMPOUND-1               RIVSTIGMINE    
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DOCKED WITH BETA SECRETASE (BACE 1 PDB ID: 1W51) 
Table No 28C: Docking against Beta Secretase enzyme 
COMP
OUND  
STRUCTURE DOCKING 
SCORE 
KCAL/MO
L 
DOCKING VIEW 
Compou
nd 1 O
O
O
OH
CH3
O
CH3
-7.837  
   
 
Rivastig
mine 
 
ON
O
CH3
CH3
N
CH
CH3
 
 
 
 
-8.543  
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Fig 59 e: Amino acid interaction with Human butyryl cholinesterase enzyme 
Compound 1 Rivastigmine 
  
HYDROGEN INTERACTIONS 
Fig 59 f: Amino acid interaction with beta secretase 
COMPOUND 1 RIVASTIGMINE
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The compound I and Rivastigmine standard were docked with the three important proteins 
which is essential for the study Alzheimer’s disease.  
It was observed that docking results were more than -7.00 Kcal/mol and less than 12.00 
Kcal/mol which indicates its activity and being less than 12.00 Kcal/mol indicates that it 
binds with the protein strongly but not so much that it cannot be released. Thus it revealed 
to have good anti Alzheimer activity.  
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SUMMARY 
The project entitled “Parmacognostical, Phytochemical and Anti alzhiemer activity 
for the peels of Citrus maxima (burm.) Merr. (Rutaceae)  using various approaches,” 
has been achieved by the following results. This work was designed for first time to notice 
isolation, characterization and docking of isolated bio active compound for its anti 
Alzheimer activity.  
 The literature survey showed that, only scrappy information was available on this 
shrub. With this scanty information on this plant consistent expectation of 
unexplored Phyto chemical profile and pharmacological efficacy under Rutaceae 
family forms the rationale for the study. 
 The Pharmacognostical studies provide a protocol of specific distinguishing 
features of the plant which is used to differentiate it from its closely related 
species. 
 Morphological study has provided a characteristic identify of peels which has 
yellowish green to yellowish brown outer surface and white to brown colour in the 
inner surface. It has sour and bitter taste with aromatic odour and surface is found 
to be spongy and pitted.  
 Anatomical studies revealed the presence of epidermal cells, parenchymal cells, 
chollenchymatous cell, oil globules and vascular bundle 
 Powder analysis showed the presence of fibers, stone cells, and abundant oil 
globules. 
 Histochemical analysis showed the presence of lignin, starch and tannins. 
 Varying physio chemical parameters such as ash values, extractive values, loss on 
drying, crude fibre content, swelling index and foaming index were studied. 
Volatile oil content were also determined as peels contain about 6% V/W of 
volatile oil. 
 Presence of calcium added up its nutritional value and could be attributed to its 
memory enhancing activity or anti Alzheimer activity. Any significant deviation in 
the percentage of mineral analysis indicates the presence of adulteration or 
substitution of drugs.  
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 The above mentioned specific characters might offer reliable clues for the correct 
identification of peels in crude as well as fragmentary form and also ensure its 
differentiation from its substituent’s and adulterants. 
 Extraction and phytochemical evaluation of them deals with chemical analysis of 
the extract used for pharmacological screening. Qualitative preliminary 
phytochemical analysis was performed to detect the phytoconstituents nature and 
their presence in powder and its various extracts. 
 Ethyl acetate extract showed the presence of steroids, flavanoids, tannins, 
triterpenoid and phenolic compound. Whereas the ethanolic extract showed the 
presence of steroids, flavanoids, phenols, phytosterol, gums and mucilage, 
carbohydrate,  triterpenoids, volatile oil. Aqueous extract showed the presence 
of steroids, flavanoids, phenols, gums and mucilage, carbohydrate and 
triterpenoid. 
 Total phenolic content and total flavanoid content of ethyl acetate and ethanol 
extract were determined quantitatively. No fluorescence was observed in powder 
and also in extract. 
 Qualitative chromatographic analysis (TLC) was performed to identify the single 
or mixture of constituents in the various extracts. The maximum number of spots 
were observed in the ethanolic extract thus it was subjected for HPTLC analysis.  
 The qualitative chromatographic High Performance Thin Layer Chromatography 
(HPTLC) analysis was performed to detect number of fractions in the extracts. The 
HPTLC of ethanolic extract showed 10 peaks. Thus the HPTLC analysis is used as 
a effective tool for analysis of active constituents and for the selection of active 
extracts. HPTLC is also used as a versatile tools for detection of impurities.  
 The active extract was selected on the basis of in vitro anti oxidant and acetyl 
cholinesterase inhibitory activities. Accordingly the ethanolic extract with 
potential anti oxidant and acetyl cholinesterase activity was selected for in vivo 
study. 
 Based on the acute toxicity studies, previously reported 1/10th and 1/5th (200 and 
400 mg/kg) of the maximum tolerated dose (2000 mg/kg B.W) were selected for 
the in vivo studies. 
 The ethanolic extract of the peels of  Citrus maxima was administered orally for 
fourteen days showed a dose dependent and significant improvement in 
Summary 
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memory of young mice and it also successfully reversed the memory deficits 
induced by Scopalamine. Furthermore a significant decreased in cholinergic 
transmission level in mice brain accounts for its multifarious beneficial effects 
such as anti alzheimer activity.  
 Ethanolic extract showed the significant anti Alzheimer activity thus it was packed 
into a column to scrutinize the phytoconstituents present in it. Single compound 
were identified by TLC analysis. They were further subjected for spectral analysis. 
 From the spectral analysis data the compound was identified as 5-hydroxy-7-
methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one. Which was a flavonoids type 
of compound which is expected to be responsible for activity. 
 Finally, the docking studies were performed by Argus Lab software and the results 
were concluded that it had good binding interaction with bio marker enzymes and 
proved for its anti alzheimer activity in molecular modeling study. 
 
Conclusion 
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CONCLUSION:  
Reports helps us to concluded that the pharmacognostical standards generated will 
be useful for the proper identification of plant and also to differentiate it from its closely 
related species and adulterants.  
With the support of in vitro studies and Phytochemical screening, the ethanol 
extract was selected and subjected to in vivo studies.  
The ethanolic extract with low and high dose in mice showed a significant activity 
anti Alzheimer activity. This may be due to one or more phytoconstituents like flavonoids 
present in it. It can be due to the isolated compound which showed good binding with the 
biomarker compounds.  
Further research work has to be carried out in order to standardize the isolated 
molecule, followed by formulation. Finally has to be screened for preclinical and clinical 
studies against Alzheimer. 
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